document incorporate reference document annual report stockholder fiscal year part ii end december proxy statement annual meeting iii stockholder hold april item business merck co inc company global researchdriven pharmaceutical product service company discover develop manufacture market broad range innovative product improve human animal health directly joint venture provide pharmacy benefit management service medco health solutions inc medco health company operation principally manage product service basis comprise reportable segment merck pharmaceutical include product market directly joint venture medco health merck pharmaceutical product consist therapeutic preventive agent sell prescription treatment prevention human disorder medco health revenue consist principally sale prescription drug manage prescription drug program home delivery pharmacy network contractually affiliate retail pharmacy service provide program help client control cost enhance quality prescription drug benefit offer member follow table show sale category company product service million atherosclerosis hypertensionheart failure antiinflammatoryanalgesic osteoporosis respiratory vaccinesbiological antibacterialantifungal ophthalmological urology human immunodeficiency virus hiv medco health total begin sale individual therapeutic class present net rebate discount amount previously present gross basis rebate discount include rebate discount include total net sale change presentation effect consolidated sale net income sale individual therapeutic class present comparable basis human health product include therapeutic preventive agent generally sell prescription treatment human disorder atherosclerosis product zocor simvastatin largestselle hypertensionheart failure product significant cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate prinivil lisinopril antiinflammatoryanalgesic include vioxx rofecoxib arcoxia etoricoxib agent specifically inhibit cox enzyme responsible pain inflammation osteoporosis product fosamax alendronate sodium treatment prevention osteoporosis respiratory product singulair montelukast sodium leukotriene receptor antagonist vaccinesbiological varivax varicella virus vaccine live live virus vaccine prevention chickenpox mmr ii measles mumps rubella virus vaccine live recombivax hb hepatitis b vaccine recombinant largestselle antibacterialantifungal product include primaxin imipenem cilastatin sodium cancidas caspofungin acetate recently launch invanz ertapenem sodium ophthalmological cosopt dorzolamide hydrochloride timolol maleate ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution largestselle urology product proscar finasteride treatment symptomatic benign prostate enlargement hiv product include crixivan indinavir sulfate protease inhibitor treatment human immunodeficiency viral infection adult primarily include sale human pharmaceutical net rebate discount pharmaceutical animal health supply sale company joint venture astrazeneca lp prilosec omeprazole nexium esomeprazole magnesium significant medco health primarily include medco health sale nonmerck product medco health pharmacy benefit service principally sale prescription drug manage prescription drug program service provide program help client control cost enhance quality prescription drug benefit member january company announce plan establish medco health separate publiclytrade company medco health convert limited liability company delaware corporation change merckmedco manage care llc medco health solutions inc july company announce solely market condition postpone initial public offering ipo share medco health withdraw associate equity registration statement company remain fully commit establishment medco health separate publiclytraded company intend complete separation mid subject market condition september food drug administration fda approve cozaar company angiotensin ii antagonist treatment high blood pressure reduce rate progression nephropathy kidney disease type diabetic patient hypertension nephropathy elevate serum creatinine proteinuria company submit supplemental new drug application fda cozaar base result losartan intervention endpoint reduction hypertension life study life study use cozaar significantly reduce combined risk cardiovascular morbidity mortality notably stroke patient hypertension leave ventricular hypertrophy compare betablocker atenolol analysis treatment effect ethnicity black patient treat atenolol low risk experience cardiovascular death heart attack stroke compare patient treat cozaar drug lower blood pressure similar degree july fda approve new mg oral granule formulation singulair treatment asthma patient age december fda approve singulair relief symptom seasonal allergic rhinitis adult child young year age january fda approve cancidas companys oncedaily intravenous antifungal medicine treatment candidemia bloodstream infection follow candida infection intraabdominal abscess peritonitis infection line abdominal cavity pleural space infection infection lining lung acquisition july company acquire rosetta inpharmatics inc publiclyheld washington base informational genomics company design develop unique technology efficiently analyze gene datum predict medical compound interact different kind cell body january company wholly own subsidiary msd japan co ltd launch tender offer acquire estimate aggregate purchase price billion remain common share banyu pharmaceutical co ltd banyu tender offer conditional company receive million common share bring share ownership banyu approximately march company announce close final count share tender offer remain share banyu company receive tender share bring ownership outstanding banyu common stock japan world second large pharmaceutical market joint venture company enter agreement astra ab astra develop market astra product united states company astra form equally own joint venture develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach line company astra restructure joint venture company acquire astras interest joint venture rename kbi inc kbi contribute kbis operating asset new limited partnership name astra pharmaceutical lp partnership company maintain limited partner interest partnership rename astrazeneca lp exclusive distributor product kbi retain right company earn certain partnership return ongoing revenue base sale current future kbi product partnership return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent company share undistribute partnership gaap earning conjunction restructure payment million astra purchase option buy company interest kbi product exclude company interest gastrointestinal medicine prilosec nexium company grant astra option share option buy company common stock interest kbi exercise price base net present value estimate future net sale prilosec nexium april astra merged zeneca group plc form astrazeneca ab astrazeneca result merger exchange company relinquishment right future astra product exist pende patent time merger astra pay million subject trueup calculation require repayment portion merger trigger partial redemption company limited partner interest furthermore result merger astrazenecas option buy company interest kbi product exercisable company right require astrazeneca purchase interest addition share option exercisable year astra purchase company interest kbi product company form joint venture johnson johnson develop market manufacture consumer health care product united states own joint venture expand europe canada european extension currently market sell overthecounter pharmaceutical product france germany italy spain united kingdom significant joint venture product pepcid ac famotidine overthecounter form company ulcer medication pepcid famotidine pepcid complete overthecounter product combine company ulcer medication antacid calcium carbonate magnesium hydroxide effective april company merck vaccine division connaught laboratories inc aventis pasteur affiliate aventis ag agree collaborate development marketing combination pediatric vaccine promote select vaccine united states research marketing collaboration enable company pool resource expedite development vaccine combine different antigen protect child variety disease include haemophilus influenzae type b hepatitis b diphtheria tetanus pertussis poliomyelitis combination vaccine development effort continue agreement vaccine currently promote company merck vaccine division pasteur mrieux connaught aventis pasteur form joint venture market human vaccine europe collaborate development combination vaccine distribution european union eu european free trade association company aventis pasteur contribute thing european vaccine business equal share joint venture know pasteur mrieux msd snc aventis pasteur msd snc joint venture subject monitor eu partner certain undertaking return exemption european competition law effective december joint venture maintain presence directly affiliate branches belgium italy germany spain france austria ireland sweden united kingdom distributor rest europe company rhnepoulenc sa combined respective animal health poultry genetic business form merial limited merial fullyintegrated animal health company standalone joint venture equally own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie december rhnepoulenc sas interest merial acquire aventis sa corporation form merger rhnepoulenc sa hoechst ag company scheringplough corporation scheringplough enter agreement create separate equally own partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area december company scheringplough announce worldwide expansion exclude japan cholesterolmanagement partnership december entity merckscheringplough pharmaceutical partnership submit new drug application nda fda zetia ezetimibe tablet cholesterol absorption inhibitor discover scheringplough administer statin reduction elevated cholesterol level october merckscheringplough pharmaceutical announce fda approval zetia oncedaily tablet zetia mg approve use statin reduce ldl cholesterol total cholesterol patient high cholesterol marketing approval receive october germany brand ezetrol use market statin treatment elevate cholesterol level march merckscheringplough pharmaceutical announce ezetrol successfully complete european union mutual recognition procedure mrp completion mrp process eu member states iceland norway grant national marketing authorization unify labeling ezetrol eu ezetrol indicate coadministration statin adjunctive therapy diet use patient primary hypercholesterolemia appropriately control statin ezetrol monotherapy indicate adjunctive therapy diet use patient primary hypercholesterolemia statin consider inappropriate tolerate addition ezetrol monotherapy indicate adjunctive therapy diet use patient homozygous familial sitosterolemia coadministere statin use patient homozygous familial hypercholesterolemia partnership pursue development marketing zetia oncedaily combination tablet zocor january merckscheringplough pharmaceutical report result phase iii clinical trial fixedcombination tablet contain singulair claritin scheringplough nonsedate antihistamine demonstrate sufficient add benefit treatment seasonal allergic rhinitis competition market companys pharmaceutical business conduct highly competitive highly regulate competition involve intensive search technological innovation ability market innovation effectively longstanding emphasis research development company prepare compete search technological innovation additional resource meet competition include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product joint venture license refine sale marketing effort address change industry condition enhance product portfolio company continue pursue external alliance earlystage latestage product opportunity include joint venture target acquisition introduction new product process competitor result price reduction product replacement product protect patent example number compound available treat disease typically increase time result slow growth sale certain company product addition particularly area human pharmaceutical product legislation enact state allow encourages instance absence specific instruction prescribe physician mandate use generic product contain active chemical innovator product brand product governmental pressure dispense generic product significantly reduce sale certain company product long protect patent vasotec vaseretic enalapril maleate combination hydrochlorothiazide right sell prinivil prinzide lisinopril combination hydrochlorothiazide pepcid mevacor lovastatin slow growth certain product medco health operate competitive market characterize increase pricing margin pressure client seek control growth cost provide prescription drug benefit member medco health compete primarily basis ability provide sophisticated program service client member pharmacy benefit plan physician pharmacy member use medco health program service help client control cost enhance quality prescription drug benefit offer member medco health accomplishes primarily negotiate competitive pricing pharmaceutical manufacturer retail pharmacy administer prescription fill national network retail pharmacy home delivery pharmacy distribution company sell human health product primarily drug wholesaler retailer hospital clinic government agency manage health care provider health maintenance organization institution companys professional representative communicate effectiveness safety value company product health care professional private practice group practice manage care organization medco health sell pharmacy benefit management service blue crossblue shield plan manage care organization insurance carrier thirdparty benefit plan administrator employer federal state local government agency unionsponsore benefit plan raw material raw material supply normally available quantity adequate meet need company business government regulation investigation pharmaceutical industry subject global regulation regional country state local agency particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states food drug administration modernization act pass culmination comprehensive legislative reform effort design streamline regulatory procedure fda improve regulation drug medical device food legislation principally design ensure timely availability safe effective drug biologic expedite premarket review process new product key provision legislation reauthorization prescription drug user fee act permit continue collection user fee prescription drug manufacturer augment fda resource earmark review human drug application help provide resource necessary ensure prompt approval safe effective new drug recent year increase number legislative proposal introduce propose congress state legislature effect major change health care system nationally state level legislative initiative introduce congress include prescription drug benefit proposal medicare beneficiary reform bill enact federal level state pass reform legislation federal state development expect company position respond evolve market force predict outcome effect legislation result reform effort year pharmaceutical industry pharmacy benefit management business federal state oversight new drug approval system drug safety advertising promotion drug purchasing reimbursement program formulary variously review company believe continue able conduct operation include introduction new drug market regulatory environment type federal initiative contain federal health care spending prospective capitate payment system implement reduce rate growth medicare reimbursement hospital system establish advance flat rate reimbursement health care patient payer fiscally responsible type payment system cost containment system widely public private payer cause hospital health maintenance organization customer company costconscious treatment decision include decision medicine available patient company continue work private federal employer slow increase health care cost company effort demonstrate medicine help save cost area price flexibility product portfolio encourage use company medicine helped offset effect increase cost pressure federal state government pursue method directly reduce cost drug pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity disproportionate share hospital hospital meet certain criterion provide minimum discount define nonfederal average manufacturer price purchase certain component federal government department veterans affairs department defense initiative state seek rebate minimum require medicaid legislation case patient eligible medicaid federal vaccine child entitlement program center disease control prevention cdc fund purchase recommend pediatric vaccine public sector price immunization medicaideligible uninsured native american certain underinsured child company award cdc contract supply pediatric vaccine program monovalent component certain vaccine outside united states company encounter similar regulatory legislative issue country business primary thrust governmental inquiry action determine drug safety effectiveness mechanism control price prescription drug profit prescription drug company eu adopt directive concern classification label advertise wholesale distribution approval marketing medicinal product human use company policy procedure consistent substance directive consequently believe material effect company business company subject jurisdiction regulatory agency subject potential administrative action action include seizure product civil criminal sanction certain circumstance company deem advisable initiate product recall company believe able compete effectively environment addition certain country eu recognize economic importance researchbase pharmaceutical industry value innovative medicine society work industry representative european commission proposal complete single market pharmaceutical improve competitive climate variety mean include market deregulation increase focus privacy issue country world include united states eu united states federal state government pursue legislative regulatory initiative patient privacy include federal recently issue state privacy regulation concern health information affect company operation particularly medco health extensive federal state regulation applicable practice pharmacy administration manage health care program state medco health operate pharmacy law regulation govern operation licensing standard professional practice pharmacist regulation issue administrative body state typically pharmacy board empower impose sanction noncompliance policy procedure medco health comply regulation patent trademark license patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product se pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance date grant legal life patent country protection afford vary country country depend type patent scope coverage patent portfolio develop product introduce company normally provide market exclusivity basic patent effect follow major product united states aggrastat tirofiban hydrochloride arcoxia cancidas comvax haemophilus b conjugate hepatitis b recombinant vaccine cosopt cozaar crixivan fosamax hyzaar invanz maxalt rizatriptan benzoate pedvaxhib haemophilus b conjugate vaccine primaxin propecia finasteride proscar recombivax hb singulair timopticxe timolol maleate ophthalmic gel forming solution trusopt vioxx zocor basic patent effect united states zetia develop merckscheringplough pharmaceutical partnership basic patent effect sustivastocrin efavirenz bristol myers squibb exclusive license company sell sustiva united states canada certain european country company market stocrin country world zocor lose basic patent protection canada certain country europe include united kingdom germany company expect decline zocor sale country fda modernization act modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant exclusivity provision reauthorize october good pharmaceuticals child act pass january fda grant additional month market exclusivity united states cozaar february singulair august zocor june expiration product patent normally result loss market exclusivity cover product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product ii patent relate use product iii patent relate novel composition formulation iv united states market exclusivity available federal law effect product patent expiration depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset general increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty receive patent knowhow license right amount million company pay royalty amount million patent knowhow license hold divestiture company sell right vasotec vaseretic vasotec iv injection enalaprilat biovail laboratory incorporate biovail subsidiary biovail corporation time company canadian subsidiary merck frosst canada co merck frosst biovail enter supply agreement merck frosst agree supply biovail minimum year bulk tablet formulate enalapril maleate enalapril maleate combination hydrochlorothiazide distribution biovail united states vasotec vaseretic basic product patent vasotec vaseretic expire united states prior transaction research development company business characterize introduction new product new use exist product strong research development program approximately people employ company research activity expenditure company research development program billion billion billion estimate grow fullyear expense company maintain ongoing commitment research broad range therapeutic area clinical development support new product total expenditure period exceed billion compound annual growth rate company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development project relate human health carry field bacterial viral infection cardiovascular function cancer diabete pain inflammation kidney function obesity mental health nervous system ophthalmic research prostate therapy respiratory system fungal disease bone disease endoparasitic ectoparasitic disease companion animal disease production improvement development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug market united states record datum preclinical clinical experience include nda biological product license application fda require approval development certain product subject government regulation cover safety efficacy united states foreign country assurance compound result particular program obtain regulatory approval necessary market february company announce discontinuing phase ii clinical trial lead gabaa aa agonist compound treatment generalize anxiety company continue research field anxiety ongoing study gaba agonist molecules time development molecule certain february banyu announce change time respect file japan nda rofecoxib vioxx press release banyu state review clinical datum accumulate date recommendation organization pharmaceutical safety research banyu agree conduct additional study japanese patient support nda filing result decision nda filing originally plan place end march delay banyu state conduct additional study appropriate support filing product new product candidate result company research development program include arcoxia second cox specific inhibitor potentially useful treatment osteoarthritis rheumatoid arthritis acute pain chronic pain dysmenorrhea company file nda fda august march company withdraw original nda investigational medicine company announce june plan refile expand nda arcoxia fda second half company plan seek indication ankylose spondylitis chronic autoimmune disease primarily involve spine osteoarthritis rheumatoid arthritis chronic pain dysmenorrhea acute gouty arthritis enhance file broad range acute pain indication company provide datum nda ongoing study arcoxia acute pain response fda request expand nda include additional cardiovascular safety datum arcoxia versus non naproxen nonsteroidal antiinflammatory drug nsaid company conduct large clinical trial obtain cardiovascular safety datum completion european union mutual recognition procedure exclude france germany national authorization grant arcoxia remain eu member states norway iceland oncedaily treatment osteoarthritis rheumatoid arthritis acute gouty arthritis arcoxia launch country include europe latin america asia pacific region expect launch country france refer cox specific inhibitor compound coxibs market regulatory review time referral committee proprietary medicinal product european scientific regulatory agency review gastrointestinal cardiovascular safety coxib class transparency commission responsible drug list pricing reimbursement process france currently reevaluate medical benefit market coxibs versus traditional nsaid product candidate emend aprepitant oral compound potentially useful prevention highly emetogenic chemotherapyinduce nausea vomit march gastrointestinal drug advisory committee fda review clinical datum emend advisory committee unanimously agree emend combination standard antiemetic therapy demonstrate efficacy prevention nausea vomit acute delay phase follow highly emetogenic chemotherapy advisory committee recommend postmarkete study gather additional information safety profile emend regimen patient receive certain chemotherapeutic agent advisory committee ask vote recommend emend approval product phase iii clinical development include oral compound potentially useful treatment depression neuropsychiatric disease compound potentially useful treatment diabetic glucose control diabetic dyslipidemia certain new vaccine include human papillomavirus vaccine hpv potentially useful prevent hpv infection rotavirus vaccine potentially useful prevention infant diarrhea dehydration cause rotavirus shingle zoster vaccine potentially useful prevention herpeszoster andor post herpatic neuralgia debilitate pain condition associate zoster compete claim intellectual property hpv field company confident claim delay company program compound potentially useful treatment chronic obstructive pulmonary disease asthma phase ii clinical development company phase clinical trial vaccine compound potentially useful treatment hivaid addition company demonstrate pharmacological proofofconcept human key biomarker determine forward clinical development new compound cancer alzheimer disease obesity diabete product service mark appear type form different surround text trademark service mark own license merck co inc subsidiarie affiliate include zetia trademark own entity merckscheringplough pharmaceutical partnership cozaar hyzaar register trademark ei du pont de nemours company wilmington de claritin trademark schering corporation prilosec nexium trademark astrazeneca group trademark vasotec vaseretic own biovail laboratory incorporate employee end company employee worldwide employ united states include puerto rico addition medco health employee employ united states approximately worldwide employee company medco health respectively represent collective bargaining group environmental matter company believe compliance material respect applicable environmental law regulation company incur capital expenditure approximately million environmental protection facility capital expenditure purpose forecast exceed million year addition company operating maintenance expenditure environmental protection facility approximately million expenditure purpose year forecast approximate million company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million estimate million year amount consider potential recovery insurer party company take active role identify provide cost management opinion liability environmental matter probable reasonably estimable accrue possible predict certainty outcome environmental matter ultimate cost remediation management believe reasonably possible expenditure incur excess provide result material adverse effect company financial position result operation liquidity capital resource cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalle forward look statement subject risk uncertaintie identify forwardlooke statement use word expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product approval development program propose initial public offer eventual divestiture medco health subsidiary carefully consider statement understand factor cause actual result differ company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially possible predict identify factor include follow generic competition product patent product recently expire united states country include product patent mevacor prinivil prinzide vaseretic zocor lose basic patent protection canada certain country europe include united kingdom germany addition patent cover omeprazole active ingredient prilosec company supply exclusively astrazeneca lp expire trial court hold october generic company omeprazole product infringe company formulation patent respect prilosec agreement astrazeneca company receive supply payment predetermine rate sale certain product astrazeneca notably prilosec nexium company anticipate total supply payment company receive astrazeneca decline midsingle digit percentage rate income contribution relate company collaboration scheringplough continue negative reflect sale ezetimibe offset launch expense product ongoing joint venture research development spending increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation enforcement thereof affect company pharmaceutical vaccine andor pharmacy benefit management business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale legal factor include product liability claim antitrust litigation governmental investigation environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include united states eu united states federal state government pursue legislative regulatory initiative patient privacy include federal recently issue state privacy regulation concern health information affect company operation particularly medco health change tax law include change relate taxation foreign earning impact legislation cap ultimately repeal section internal revenue code relate earning company puerto rican operation change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board securities exchange commission adverse company risk initial public offering divestiture interest medco health complete economic stock market condition generally particularly respect pharmacy benefit management industry tax consideration failure meet customary condition economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertaintie geographic area segment information company operation outside united states conduct primarily subsidiarie sale company human health product subsidiary outside united states company human health sale respectively company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition recent year company expand operation country locate latin america middle east africa eastern europe asia pacific change government policy economic condition make possible company earn fair return business develop area stable offer important opportunity growth time financial information geographic area operate segment company business incorporate reference page begin caption segment reporting company annual report stockholder matter board director company determine dr heidi g miller currently executive vice president chief financial officer bank corporation previously chief financial officer different public company audit committee financial expert board director qualitative assessment dr miller level knowledge experience base number factor include formal education experience chief financial officer report company board director determine dr miller independent management company available free charge internet website annual report quarterly report form q current report form k amendment report file furnish pursuant section security exchange act soon reasonably practicable report electronically file furnish securities exchange commission company internet website address wwwmerckcom item property companys corporate headquarters locate whitehouse station new jersey companys pharmaceutical business conduct divisional headquarters locate upper gwynedd west point pennsylvania principal research facility human health product locate rahway new jersey west point company production facility human health product location united states puerto rico branch warehouse provide service country outside united states subsidiary company own interest manufacturing plant property australia canada countries western europe central south america africa asia medco health operate primary business headquarters locate franklin lake new jersey own lease facility location united states capital expenditure million compare million united state amount million million abroad expenditure amount million million company subsidiarie principal facility manufacturing plant title consider satisfactory company consider property good operating condition machinery equipment maintain plant manufacture product suitable intend purpose capacity project capacity adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action company include medco health party number antitrust suit certain certify class action institute nation retail pharmacy consumer state allege conspiracy restraint trade challenge pricing andor purchasing practice company medco health respectively significant number pharmaceutical company wholesaler sue similar litigation action action pende state court consolidate pretrial purpose united states district court northern district illinois company defendant finalize agreement settle federal class action allege conspiracy represent single large group retail pharmacy claim time company enter settlement satisfactory term october judicial panel multidistrict litigation panel determine consolidated pretrial proceeding federal district court chicago substantially complete panel order federal antitrust conspiracy case settle company return federal district court case originally file case return court transfer federal court brooklyn new york proceeding company engage conspiracy admission wrongdoing include settlement agreement feasible predict final outcome remain proceeding opinion company proceeding ultimately result liability material adverse effect financial position liquidity result operation company previously disclose company advise department justice investigate marketing selling activity company pharmaceutical manufacturer company work government respond appropriately informational request company join ongoing litigation allege manipulation pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level judicial panel multidistrict litigation order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidated class action complaint aggregate claim previously file federal district court action expand number manufacturer include like company defendant prior pende case company motion dismiss case pende court boston addition company thirty pharmaceutical manufacturer recently name similar complaint file federal court new york new york county suffolk company believe lawsuit completely merit vigorously defend january department justice notify federal court new orleans louisiana go intervene pende federal false claim act case file seal december company court issue order unseal complaint file physician louisiana ordered complaint serve complaint allege company discount pepcid certain louisiana hospital lead increase cost medicaid company believe complaint completely merit vigorously defend previously report dispute company pharmacia corporation pharmacia compete claim patent right class compound include rofecoxib active ingredient vioxx settle worldwide basis party result company maintain worldwide exclusive patent right vioxx number federal state lawsuit involve individual claim purport class action file company respect vioxx lawsuit defendant pfizer inc pharmacia market compete product certain lawsuit include allegation gastrointestinal bleed cardiovascular event company believe lawsuit completely merit vigorously defend company party claim bring consumer protection act united kingdom allege certain child suffer variety condition result vaccinate bivalent vaccine measle rubella trivalent vaccine measle mump rubella include company mmr ii pharmaceutical company sue claimant allege adverse consequence include autism inflammatory bowel disease epilepsy diabete encephalitis encephalopathy chronic fatigue syndrome lead case select trial schedule commence april company company trial case initially limit issue causation defect condition autistic spectrum disorder inflammatory bowel disease company believe lawsuit completely merit vigorously defend company party individual class action product liability lawsuit claim united states involve pediatric vaccine ie hepatitis b vaccine haemophilus influenza type b vaccine contain thimerosal preservative vaccine defendant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result thimerosal introduce develop body company successful case dismiss stay ground national vaccine injury compensation program nvicp prohibit person file maintain civil action seek damage vaccine manufacturer vaccinerelate injury petition file united states court federal claim number similar case mmr ii andor thimerosalcontaining vaccine file united states court federal claim nvicp procedure process case contemplate decision general causation issue july company believe lawsuit claim completely merit vigorously defend proceeding party time time generic manufacturers pharmaceutical product file abbreviate new drug application anda fda seek market generic form company product prior expiration relevant patent own company generic pharmaceutical manufacturer submit andas fda seek market united states generic form fosamax prilosec prior expiration company astrazenecas case prilosec patent concern product generic company anda include allegation noninfringement invalidity unenforceability patent generic manufacturer receive fda approval market generic form prilosec company file patent infringement suit federal court company file andas generic alendronate astrazeneca company file patent infringement suit federal court company file andas generic omeprazole case alendronate similar patent challenge exist certain foreign jurisdiction company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity product trial united states respect alendronate daily product conclude november november decision issue district court delaware find company patent valid infringe appeal file defendant trial united states involve alendronate weekly product hold march decision expect january high court justice england wale hold patent company protect alendronate daily weekly product invalid united kingdom company proceed appeal decision case omeprazole trial court united states render opinion october uphold validity company astrazenecas patent cover stabilize formulation omeprazole rule defendant omeprazole product infringe patent defendant product find infringe formulation patent appeal file party trial respect certain generic manufacturer omeprazole product trial date set previously disclose company name defendant number purport class action lawsuit shareholder derivative action relate company revenue recognition practice retail copayment pay individual medco health provide pharmaceutical benefit recently class action lawsuit consolidate amend assert claim company medco health certain officer director relate company revenue recognition practice retail co payment rebate receive medco health medco healths independent status company believe lawsuit completely merit vigorously defend company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability de minimis cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify provide cost amount include reduction anticipate recovery cleanup cost insurer site owner operator recalcitrant potentially responsible party medco health recently company medco health agree settle class action basis series lawsuit assert violation employee retirement income security act erisa company medco health certain plaintiff counsel file settlement federal district court new york plaintiff pharmaceutical benefit plan medco health pharmacy benefit manager file case propose class action settlement agree plaintiff initial case gruer case file medco health company propose settlement court preliminarily approve company medco health agree pay million medco health agree change continue certain specify business practice period year financial compensation intend benefit member settlement class include erisa plan medco health administer pharmacy benefit time december settlement preliminarily approve class member plan opportunity participate opt settlement court schedule hearing purpose determine fairness settlement class member initial plaintiff group lawyer file additional erisa lawsuit company medco health expect oppose settlement settlement final district court grant final approval appeal resolve medco health company agree propose settlement order avoid significant cost distraction protract litigation gruer case similar claim pharmaceutical benefit manager pende case allege medco health treat fiduciary erisa medco health breach fiduciary duty benefit plan amend complaint gruer case allege company medco health violate erisa medco health increase company market share enter certain prohibit transaction favor company product plaintiff demand medco health company turn unlawfully obtain profit trust set benefit plan plaintiff indicate amend complaint medco health allege violation sherman act clayton act state antitrust law allege conspiracy suppress price competition unlawful combination allegedly result high pharmaceutical price similar complaint medco health company assert claim breach fiduciary duty erisa file additional action plan participant purportedly behalf plan action similarlysituate self fund plan class action status seek action plan decide opt participate propose settlement discuss party lawsuit amend complaint action allege activity company medco health violate federal state racketeering law addition propose class action complaint medco health company file trustee benefit plan complaint action rely theory litigation discuss lawsuit base allegation pende medco health federal court california state court new jersey theory liability action company defendant base california statute prohibit unfair business practice plaintiff purport sue behalf general public california seek injunctive relief disgorgement revenue allegedly improperly receive company medco health theory liability new jersey action base new jersey consumer protection statute plaintiff purport represent class similarlysituate non erisa plan seek compensatory treble damage new jersey court dismiss new jersey action reinitiate certain circumstance medco health company believe case completely merit medco health fiduciary mean erisa company medco health violate erisa california unfair business practice law new jersey consumer protection law medco health company intend vigorously defend remain claim previously disclose august medco health receive letter civil division united states attorney office eastern district pennsylvania relate ongoing investigation pharmacy benefit management industry letter government provide medco health preliminary assessment investigation summarize remedy government seek prove violation law company standpoint letter raise significant new issue letter government state prepare decide intervene qui tam whistleblow action pende eastern district pennsylvania medco health previously disclose government letter specifically state issue formal demand offer settle settlement recommendation medco health believe practice comply legal requirement medco health continue engage dialogue government respect matter legal proceeding involve company medco health principally product liability intellectual property suit involve company pende feasible predict outcome proceeding opinion company proceeding adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company medco health addition time time federal state regulator seek information practice industry company medco health operate feasible predict outcome request information company medco health expect inquiry material adverse effect financial position liquidity result operation company medco health item submission matter vote security holder applicable executive officer registrant march raymond v gilmartin age june chairman board november president chief executive officer david w anstice age january president human health responsible company prescription drug business japan latin america canada australia new zealand company joint venture relationship scheringplough march president america human health responsible prescription drug division comprise human health company prescription drug business canada latin america company joint venture relationship scheringplough january president human healththe americas responsible company human health business united states canada latin america marcia j avedon age january senior vice president human resource september vice president talent management organization effectiveness prior september dr avedon hold senior human resource position honeywell international diversified manufacturing technology company robert h boisclair age january act president merck manufacturing division mmd march senior vice president operation america mmd richard clark age january chairman president chief executive officer medco health solutions inc merckmedco manage care llc medco health whollyowne subsidiary company january president medco health june executive vice presidentchief operating officer medco health celia colbert age january vice president secretary september assistant general counsel november caroline dorsa age august vice president treasurer responsible company treasury tax function provide financial support merck manufacturing merck research laboratory division human resource september vice president treasurer responsible company treasury tax function provide financial support asia pacific division february vice president treasurer responsible company treasury tax function january vice president treasurer january kenneth c frazi age december senior vice president general counsel responsible legal public affair function merck company foundation notforprofit charitable organization affiliate company january vice president deputy general counsel january vice president public affairs april assistant general counsel responsible public affair corporate legal activity merck company foundation richard c henriques jr age august vice president controller responsible corporate controller group provide financial support human health operation united states canada latin america europe middle east africa japan australianew zealand merck vaccine division mvd november vice president controller responsible corporate controller group provide financial support human health canada latin america americas mvd february vice president controller responsible corporate controller group provide financial support america january vice president controller january americas peter kim age january president merck research laboratory mrl february executive vice president research development mrl prior february dr kim serve member whitehead institute professor biology massachusetts institute technology investigator howard hughes medical institute judy c lewent age january executive vice president chief financial officer president human health asia responsible financial corporate development function internal auditing corporate licensing company prescription drug business asia north asia south company joint venture relationship merck capital ventures llc subsidiary company february executive vice president chief financial officer responsible financial corporate development function internal auditing corporate licensing company joint venture relationship merck capital ventures llc november senior vice president chief financial officer responsible financial corporate development function internal auditing corporate licensing company joint venture relationship merck capital ventures llc january senior vice president january chief financial officer april responsible financial corporate development function internal auditing company joint venture relationship adel mahmoud age president merck vaccines november executive vice president merck vaccines prior november dr mahmoud john h hord professor chairman department medicine physicianinchief case western reserve university university hospitals cleveland margaret g mcglynn age january president human health responsible prescription drug division hospital specialty product franchise comprise human health ushh manage care group ushh august executive vice president customer marketing sale ushh november senior vice president worldwide human health marketing august senior vice president health utilization management medco health solutions inc whollyowne subsidiary company bradley sheare age january president human health responsible prescription drug division primary care product franchise comprise human health ushh march president human health responsible prescription drug division hospital specialty product franchise comprise ushh july vice president hospital marketing sale ushh vice president antiinfective therapeutic business group ushh joan e wainwright age january vice president public affairs june vice president corporate communication public affair prior june ms wainwright deputy commissioner communication social security administration woldolsen age january president human healtheurope middle east africa responsible company prescription drug business europe middle east africa worldwide human health marketing officer list serve pleasure board director officer elect pursuant arrangement understand officer board family relationship officer list ii item market registrant common equity relate stockholder matter information require item incorporate reference page company annual report stockholder item select financial datum information require item incorporate reference datum fiscal year company include result year yearend position select financial datum table company annual report stockholder item management discussion analysis financial condition result operation information require item incorporate reference page company annual report stockholder item quantitative qualitative disclosure market risk information require item incorporate reference page company annual report stockholder item financial statement supplementary datum financial statement consolidate balance sheet merck co inc subsidiary december relate consolidated statement income retain earning comprehensive income cash flow year period end december report date january pricewaterhousecooper llp independent public accountant copy report date january previously issue arthur andersen llp independent public accountant incorporate reference page respectively company annual report stockholder b supplementary datum select quarterly financial datum incorporate reference datum contain condense interim financial datum table company annual report stockholder item change disagreement accountant account financial disclosure february board directors company audit committee dismiss arthur andersen llp arthur andersen aa company independent public accountant engage pricewaterhousecooper llp pwc serve company independent public accountant fiscal year appointment pwc ratify stockholder company annual meeting stockholder arthur andersens report company consolidate financial statement year end contain adverse opinion disclaimer opinion qualify modify uncertainty audit scope accounting principle year end december march disagreements arthur andersen matter accounting principle practice financial statement disclosure auditing scope procedure resolve aas satisfaction cause reference subject matter connection report company consolidate financial statement year reportable event define item av regulation sk company provide arthur andersen copy forego disclosure copy aas letter date march state agreement statement incorporate reference exhibit file annual report fiscal year end december year end december date board decision company consult pwc respect application accounting principle specify transaction complete propose type audit opinion render company consolidate financial statement matter reportable event set forth item ii regulation sk iii item director executive officer registrant require information director nominee incorporate reference page company proxy statement annual meeting stockholder hold april information executive officer set forth document page require information compliance section security exchange act incorporate reference caption section beneficial ownership report compliance company proxy statement annual meeting stockholder hold april item executive compensation information require item incorporate reference page caption compensation committee interlock insider participation caption compensation director begin caption compensation benefit committee report executive compensation begin caption annual benefit payable merck co inc retirement plan companys proxy statement annual meeting stockholder hold april item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference page caption security ownership certain beneficial owner management company proxy statement annual meeting stockholder hold april information respect equity compensation plan incorporate reference page begin caption equity compensation plan information company proxy statement annual meeting stockholder hold april item certain relationship relate transaction information require item incorporate reference caption relationship outside firm page caption indebtedness management company proxy statement annual meeting stockholder hold april item control procedure base evaluation date day file date company chief executive officer chief financial officer conclude company disclosure control procedure define rule ac dc securities exchange act amend effective significant change internal control factor significantly affect control subsequent date evaluation include corrective action regard significant deficiency material weakness iv item exhibit financial statement schedule report form k document file financial statement follow consolidated financial statement report independent public accountant incorporate reference company annual report stockholder note document consolidate statement income year end december consolidated statement retain earning year end december consolidate statement comprehensive income year end december consolidated balance sheet december consolidate statement cash flow year end december note consolidated financial statement report pricewaterhousecooper llp independent public accountant copy report date january previously issue arthur andersen llp independent public accountant financial statement schedule schedule omit require applicable financial statement affiliate carry equity basis omit consider individually aggregate affiliate constitute significant subsidiary exhibit exhibit number description method file master restructuring agreement date june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical lp portion exhibit subject request confidential treatment file commission restate certificate incorporation merck co inc september incorporate reference form q quarterly report period end september bylaw merck co inc amend effective incorporate reference february form q quarterly report period end march incorporate reference form q quarterly report period end june exhibit number description method file executive incentive plan amend effective february incorporate reference annual report fiscal year end december base salary deferral plan adopt october effective incorporate reference january annual report fiscal year end december merck co inc deferral program amend restate incorporate reference january registration statement form incentive stock plan amend effective incorporate reference february annual report fiscal year end december incentive stock plan amend november incorporate reference form q quarterly report period end june incentive stock plan amend restate incorporate reference february annual report fiscal year end december nonemployee director stock option plan amend restate february incorporate reference annual report fiscal year end december nonemployee director stock option plan amend incorporate reference april form q quarterly report period end june nonemployee directors stock option plan amend incorporate reference april form q quarterly report period end june supplemental retirement plan amend effective incorporate reference january annual report fiscal year end december retirement plan director merck co inc amend restate june incorporate reference form q quarterly report period end june management contract compensatory plan arrangement exhibit number description method filing plan defer payment director compensation amend restate file document january limited liability company agreement merck capital ventures llc date incorporate reference november annual report fiscal year end december agreement date january edward scolnick merck co file document inc amend restate license option agreement date july astra ab astra merck inc kbi share option agreement date july astra ab merck co inc merck holdings inc kbie asset option agreement date july astra ab merck co inc astra merck inc astra merck enterprises inc kbi supply agreement date july astra merck inc astra pharmaceutical lp portion exhibit subject request confidential treatment file commission second amend restate manufacturing agreement date july merck co inc astra ab astra merck inc astra usa inc limited partnership agreement date july kb usa lp kbi sub inc distribution agreement date july astra merck enterprises inc astra pharmaceutical lp agreement incorporate define term date june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical lp computation ratio earning fix charge file document annual report stockholder portion incorporate reference file document document deem file letter arthur andersen llp securities exchange commission date incorporate reference march form ka amendment current report form k date march list subsidiary file document consent independent public accountant contain report management contract compensatory plan arrangement incorporate reference form q quarterly report period end june exhibit number description method filing notice consent arthur andersen llp file document power attorney file document certify resolution board director file document letter registrant securities exchange commission relate arthur incorporate reference andersen llp annual report fiscal year end december certification chief executive officer pursuant usc section file document adopt pursuant section sarbanesoxley act certification chief financial officer pursuant usc section file document adopt pursuant section sarbanesoxley act instrument define right holder longterm debt company subsidiary exhibit number file total security authorize instrument take individually exceed total asset company subsidiary consolidate basis company agree furnish copy instruments commission request copy exhibit obtain stockholder write request direct stockholder service department merck co inc po box ws ab whitehouse station new jersey accompanied check payable merck co inc cover processing mailing cost b report form k threemonth period end december company furnish current report form k item regulation fd disclosure report date furnish october earning quarter certain supplemental information report date furnish december financial guidance report date furnish december press release issue medco health solutions inc wholly own subsidiary registrant report date furnish december analyst business briefing presentation report date furnish december company business briefing analyst signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize ate march merck co inc raymond v gilmartin chairman board president chief executive officer c elia c olbert celia colbert celia colbert attorneyinfact pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date raymond v gilmartin chairman board president chief march executive officer principal executive officer director judy c lewent executive vice president chief financial officer march president human health asia principal financial officer richard c henriques jr vice president controller principal accounting march officer lawrence bossidy director march william g bowen director march johnnetta b cole director march william daley director march william b harrison jr director march william n kelley director march heidi g miller director march thomas e shenk director march anne tatlock director march samuel thi director march celia colbert signing hereto sign document pursuant power attorney duly execute person name file security exchange commission exhibit document behalf person capacity date state person include majority director company c elia c olbert celia colbert celia colbert attorneyinfact certification raymond v gilmartin certify review annual report merck co inc base knowledge annual report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover annual report base knowledge financial statement financial information include annual report fairly present material respect financial condition result operation cash flow registrant period present annual report registrant certify officer responsible establish maintain disclosure control procedure define exchange act rule registrant design disclosure control procedure ensure material information relate registrant include consolidated subsidiary known entity particularly period annual report prepare b evaluate effectiveness registrant disclosure control procedure date day prior filing date annual report evaluation date c present annual report conclusion effectiveness disclosure control procedure base evaluation evaluation date registrant certify officer disclose base recent evaluation registrant auditor audit committee registrant board director person perform equivalent function significant deficiency design operation internal control adversely affect registrant ability record process summarize report financial datum identify registrant auditor material weakness internal control b fraud material involve management employee significant role registrant internal control registrant certify officer indicate annual report significant change internal control factor significantly affect internal control subsequent date recent evaluation include corrective action regard significant deficiency material weaknesse date march r aymond v g ilmartin raymond v gilmartin chairman president chief executive officer certification judy c lewent certify review annual report merck co inc base knowledge annual report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover annual report base knowledge financial statement financial information include annual report fairly present material respect financial condition result operation cash flow registrant period present annual report registrant certify officer responsible establish maintain disclosure control procedure define exchange act rule registrant design disclosure control procedure ensure material information relate registrant include consolidated subsidiary known entity particularly period annual report prepare b evaluate effectiveness registrant disclosure control procedure date day prior filing date annual report evaluation date c present annual report conclusion effectiveness disclosure control procedure base evaluation evaluation date registrant certify officer disclose base recent evaluation registrant auditor audit committee registrant board director person perform equivalent function significant deficiency design operation internal control adversely affect registrant ability record process summarize report financial datum identify registrant auditor material weakness internal control b fraud material involve management employee significant role registrant internal control registrant certify officer indicate annual report significant change internal control factor significantly affect internal control subsequent date recent evaluation include corrective action regard significant deficiency material weaknesse date march j udy c l ewent judy c lewent executive vice president chief financial officer president human health asia exhibit consent independent public accountant consent incorporation reference registration statement form nos form nos merck co inc report date january relate financial statement appear company annual report stockholder incorporate annual report pricewaterhousecooper llp florham park new jersey march exhibit index exhibit number description method file master restructuring agreement date june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical lp portion exhibit subject request confidential treatment file commission restate certificate incorporation merck co inc incorporate reference form q quarterly september report period end september bylaw merck co inc amend effective incorporate reference form q quarterly february report period end march executive incentive plan amend effective incorporate reference annual february report fiscal year end december base salary deferral plan adopt october incorporate reference annual effective january report fiscal year end december merck co inc deferral program amend restate incorporate reference registration statement january form incentive stock plan amend effective february incorporate reference annual report fiscal year end december incentive stock plan amend november incorporate reference form q quarterly report period end june incentive stock plan amend restate incorporate reference annual february report fiscal year end december nonemployee director stock option plan amend incorporate reference annual restate february report fiscal year end december nonemployee director stock option plan incorporate reference form q quarterly amend april report period end june management contract compensatory plan arrangement incorporate reference form q quarterly report period end june exhibit number description method file nonemployee director stock option plan incorporate reference form q quarterly amend april report period end june supplemental retirement plan amend effective incorporate reference annual january report fiscal year end december retirement plan director merck co inc incorporate reference form q quarterly amend restate june report period end june plan defer payment director compensation file document amend restate january limited liability company agreement merck capital incorporate reference annual venture llc date report fiscal year end december november agreement date january edward file document scolnick merck co inc amend restate license option agreement date july astra ab astra merck inc kbi share option agreement date july astra ab merck co inc merck holdings inc kbie asset option agreement date july astra ab merck co inc astra merck inc astra merck enterprises inc kbi supply agreement date july astra merck inc astra pharmaceutical lp portion exhibit subject request confidential treatment file commission second amend restate manufacturing agreement date july merck co inc astra ab astra merck inc astra usa inc limited partnership agreement date july kb usa lp kbi sub inc distribution agreement date july astra merck enterprises inc astra pharmaceutical lp management contract compensatory plan arrangement incorporate reference form q quarterly report period end june exhibit number description method filing agreement incorporate define term date june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical lp computation ratio earning fix charge file document annual report stockholder portion file document incorporate reference document deem file letter arthur andersen llp security incorporate reference form ka exchange commission date march amendment current report form k date march list subsidiary file document consent independent public accountant contain report notice consent arthur andersen llp file document power attorney file document certify resolution board director file document letter registrant security exchange incorporate reference annual commission relate arthur andersen llp report fiscal year end december certification chief executive officer pursuant file document usc section adopt pursuant section sarbanesoxley act certification chief financial officer pursuant file document usc section adopt pursuant section sarbanesoxley act incorporate reference form q quarterly report period end june instrument define right holder longterm debt company subsidiary exhibit number file total security authorize instrument take individually exceed total asset company subsidiary consolidate basis company agree furnish copy instruments commission request exhibit merck co inc plan defer payment director compensation amend restate january table content article purpose article ii election deferral measurement method distribution schedule article iii valuation defer amount article iv redesignation deferral account article v payment defer amount article vi designation beneficiary article vii plan amendment termination schedule measurement method imerck co inc plan defer payment director compensation purpose provide arrangement director merck co inc current employee elect voluntarily defer payment annual retainer meeting committee fee termination service director ii value compensation mandatorily defer behalf ii election deferral measurement method distribution schedule election voluntary deferral prior december year director entitle irrevocable election defer termination service director receipt payment retainer month begin april calendar year b committee chairperson retainer begin april calendar year c meeting committee fee month begin april calendar year prior commencement duty director director newly elect appoint board calendar year election paragraph portion voluntary deferral applicable director year service thereof voluntary deferral shall credit follow meet committee fee defer credit day director services render board retainer andor committee chairperson retainer defer prorata share defer retainer credit business day calendar quarter date voluntary deferral part thereof credit director defer account hereinafter refer voluntary deferral date b mandatory deferral friday follow company annual meeting stockholder friday hereinafter refer mandatory deferral date director credit equivalent onethird annual cash retainer month period begin april precede annual meeting mandatory deferral mandatory deferral measure merck common stock account director newly elect appoint board mandatory deferral date credit pro rata portion mandatory deferral applicable director year service thereof pro rata portion shall credit director account day director service c election measurement method annual election refer section shall include election measurement method method value amount defer measured accordance article iii available measurement method set forth schedule hereto election distribution schedule annual election refer section shall include election receive payment follow termination service director voluntary deferral amount mandatory deferral amount lump sum immediately year termination quarterly annual installment year iii valuation defer amount common stock initial credit annual mandatory deferral shall determine number partial share merck common stock purchase closing price common stock new york stock exchange mandatory deferral date portion voluntary deferral allocate merck common stock shall determine number partial share merck common stock purchase closing price common stock new york stock exchange applicable voluntary deferral date determine committee director board director measurement merck common stock mandatory voluntary deferral date constitute fair market value committee shall decide date fair market value shall determine valuation method set forth article iii section time deferral period share merck common stock purchase earmark defer amount right shareholder exist respect amount dividend director account credit additional number partial share merck common stock purchasable dividend share previously credit account closing price common stock new york stock exchange date dividend pay distribution distribution merck common stock account value closing price merck common stock new york stock exchange distribution date b mutual fund initial crediting allocate mutual fund shall determine partial mutual fund share purchase closing net asset value mutual fund share mandatory voluntary deferral date whichever applicable director account credit number partial mutual fund share determine time deferral period mutual fund share purchase earmark defer amount right shareholder exist respect amount dividend director account credit additional number partial mutual fund share purchasable close net asset value mutual fund share date dividend pay mutual fund share dividend pay number share previously credit account include pro rata dividend partial share distribution mutual fund distribution value base close net asset value mutual fund share distribution date c adjustment event reorganization recapitalization stock split stock dividend combination share merger consolidation right offering change corporate structure share company mutual fund number kind share unit investment measurement method available plan credit director account shall adjust accordingly iv redesignation deferral account general director request change measurement method value portion hisher account merck common stock amount defer merck common stock method earning attributable deferral redesignate change effective day redesignation request receive pursuant administrative guideline establish human resource financial service area treasury department provide request receive prior close new york stock exchange day ii follow business day request receive new york stock exchange close b redesignation occur active service limit number time director redesignate portion hisher defer account permit redesignated request shall irrevocable designate percentage dollar death follow death director legal representative beneficiary director redesignate subject rule active director set forth article iv section b c valuation amount redesignate portion director account redesignate value cash equivalent cash equivalent convert share unit measurement method purpose redesignation cash equivalent value mutual fund share shall close net asset value mutual fund day redesignation request receive pursuant administrative guideline establish human resource financial service area treasury department provide request receive prior close new york stock exchange day ii follow business day request receive new york stock exchange close v payment defer amount payment payment director amount defer cash accordance distribution schedule elect director pursuant article ii section distribution shall pro rata measurement method distribution shall value fifteenth day distribution month day business day business day pay soon possible b change distribution schedule prior termination request director time calendar year immediately precede calendar year service director expect terminate committee director board director committee director sole discretion authorize extension payment period originally elect director exceed allowable article ii section andor b payment frequency different originally elect director request regard amount defer december merck common stock method earning attributable deferral deferral merck common stock december earning thereon distribute accordance schedule elect director article ii section determine committee director article vi c posttermination change distribution schedule follow termination service director director request extension period distribution hisher defer compensation request received committee director prior distribution participant hisher previously elect distribution schedule revise distribution schedule exceed deferral period allowable article ii section c request grant new payment schedule determine sole discretion committee director request regard amount defer december merck common stock method earning attributable deferral retire director subject income tax petition committee director change payment frequency include lump sum distribution committee director grant petition discretion consider reasonable justification therefor deferral merck common stock december earning thereon distribute accordance schedule elect director article ii section determine committee director article vi forfeiture director defer attributable mandatory deferral earning thereon shall forfeit removal director determination committee director sole discretion director join board manage operate participate material way enter employment perform consulting service connect material manner company corporation enterprise firm limited partnership partnership person sole proprietorship business entity determine committee director sole discretion competitive business company subsidiary affiliate competitor ii directly indirectly acquire equity interest percent great competitor iii disclose material trade secret material confidential information include customer list relate company business company include competitor vi designation beneficiary event death director defer date death shall pay name beneficiary beneficiary designate director beneficiary designate director legal representative installment committee director sole discretion determine vii plan amendment termination committee director shall right amend terminate plan time reason schedule measurement method january january merck common stock mutual fund american century emerge market fund american century europacific growth fund fidelity destiny fidelity dividend growth fidelity equity income fund fidelity lowprice stock fund fidelity retirement money market fidelity spartan government income fidelity spartan equity index franklin smallmid cap growth janu enterprise janu growth income liberty acorn z pimco foreign bond institutional pimco long term government institutional pimco total return institutional putnam global equity fund putnam international voyager putnam vista rowe price blue chip growth fund vanguard asset allocation september september investment briefly name putnam global growth fund result merger september putnam global equity fund putnam global growth fund merge fund briefly retain putnam global growth fund effective october merge fund change putnam global equity fund schedule measurement method effective january merck common stock mutual fund american century emerge market institutional american fund europacific growth fund fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowprice stock fidelity retirement money market fidelity spartan government income fidelity spartan equity index franklin smallmid cap growth janu enterprise janu growth income liberty acorn class z pimco foreign bond institutional pimco long term government institutional pimco total return institutional putnam global equity putnam international voyager putnam vista rowe price blue chip growth vanguard asset allocation exhibit agreement dr edward scolnick dr scolnick express interest relinquish executive duty devote time research activity remain employ merck co inc merck company merck wish continue support benefit dr scolnicks outstanding research ability insight knowledge agree follow change title job responsibility effective close business december dr scolnick voluntarily relinquish position title responsibility merck executive vice president science technology b president merck research laboratory mrl c member mercks management committee member mrls research management committee e member board directors merck subsidiary unit merck f member merck committee currently serve consideration therefor merck appoint dr scolnick president emeritus mrl effective january capacity dr scolnick report merck chief executive officer responsible engage scientific research field choice subject approval president mrl west point laboratory enable dr scolnick engage scientific research president emeritus mrl merck assign laboratory appropriate research merck facility west point pennsylvania b allot annual budget determine president mrl shall million supply equipment material scientific staff need laboratory c assign time administrative assistant dr scolnick responsible administering budget supervising staff begin later december continue long laboratory available paragraph dr scolnick submit mercks board director annual progress report describe activity result laboratory assign merck compensation commencing january dr scolnicks base salary month subject appropriate payroll tax withholding deduction continue eligible participate employee benefit plan cover merck salary exempt employee eligible aip eip bonus annual stock option grant subject approval compensation benefit committee mercks board director dr scolnick eligible receive eip bonus payable performance addition dr scolnick remain employee merck merck allow reasonable use merck corporate aircraft available attend conference external board meeting term condition employment merck employee dr scolnick employee continue abide bind condition employment agreement signed copy annex hereto incorporate attachment include limited dr scolnick promise authorization disclose confidential information knowledge datum property relate belong merck b engage activity conflict impairs obligation merck employee c invention discoverie technical business innovation develop conceive solely jointly period employment line activity operation work investigation employment relate receive information employment ii result suggest work merck shall property merck endeavor assist company obtain protect enforce property ownership right patent invention discovery innovation retirement notwithstanding contrary retirement plan salary employee merck co inc qualified plan merck co inc supplemental retirement plan srp qualified plan retirement plan dr scolnick final average compensation term retirement plan shall employment terminate december provide extent use final average compensation cause increase benefit payable aggregate retirement plan increase shall payable srp b termination employment dr scolnick entitle treat retiree merck welfare pension saving stock option plan deferral program accord term plan effect time time specifically provide agreement provide submit appropriate paperwork require company retirement process termination employment event merck terminate dr scolnicks employment reason cause provide dr scolnick execute releasewaiver claim noncompetenonsolicitation agreement form satisfactory merck provide dr scolnick violate condition employment agreement annex hereto attachment termination employment occur dr scolnicks th birthday merck shall onetime grant academic institution designate dr scolnick sole purpose enable set maintain research laboratory employee institution academic institution designate dr scolnick year termination employment event termination dr scolnick th birthday merck shall step necessary ensure dr scolnicks year credit service mean retirement plan shall extent use credit service cause increase benefit payable aggregate retirement plan increase shall payable srp purpose paragraph termination dr scolnicks employment reason cause shall deem occur dr scolnicks resignation retirement day merck advise dr scolnick long support research dr scolnick laboratory assign agreement ii reduce annual funding laboratory million effective date agreement effective execution party subject approval merck board director applicable law party acknowledge dr scolnicks employment relationship merck form law state new jersey united states question scope interpretation effect agreement resolve substantive procedural law state new jersey complete agreement agreement constitute complete final agreement party supersede replace prior contemporaneous agreement negotiation discussion relate subject matter agreement agreement shall bind merck dr scolnick include limitation agreement single integrate writing title agreement sign merck dr scolnick merck co inc e dward colnick md r aymond v g ilmartin edward scolnick md raymond v gilmartin date december date january exhibit merck co inc subsidiarie computation ratio earning fix charge million ratio datum year end december income taxis add subtract onethird rent interest expense gross interest capitalize net amortization equity income loss affiliate net distribution prefer stock dividend net tax earning onethird rent interest expense gross prefer stock dividend fix charge ratio earning fix charge purpose compute ratio earning consist income taxis onethird rent deem company representative interest factor inherent rent interest expense net amount capitalize equity income loss affiliate net distribution dividend prefer stock subsidiary company fix charge consist onethird rent interest expense report company consolidate financial statement dividend prefer stock subsidiary companiestable content financial section content financial review description merck business competition health care environment business strategy joint venture equity method affiliate foreign operation operating result capital environmental expenditure analysis liquidity capital resource recently issue accounting standard critical accounting policy matter cautionary factor affect future result dividend pay common share condense interim financial datum common stock market price consolidate statement income consolidate statement retain earning consolidate statement comprehensive income consolidate balance sheet consolidate statement cash flow note consolidated financial statement management report audit committee report compensation benefit committee report report independent public accountant select financial datum financial review description merck business merck global researchdriven pharmaceutical product service company discover develop manufacture market broad range innovative product improve human animal health directly joint venture provide pharmacy benefit management service medco health solutions inc medco health sale million atherosclerosis hypertensionheart failure antiinflammatoryanalgesic osteoporosis respiratory vaccinesbiological antibacterialantifungal ophthalmological urology human immunodeficiency virus hiv medco health beginning sale individual therapeutic class present net rebate discount amount previously present gross basis rebate discount include rebate discount include total net sale change presentation effect consolidated sale net income sale individual therapeutic class present comparable basis human health product include therapeutic preventive agent generally sell prescription treatment human disorder atherosclerosis product zocor largestselle hypertensionheart failure product significant cozaar hyzaar vasotec prinivil antiinflammatoryanalgesic include vioxx arcoxia agent specifically inhibit cox enzyme responsible pain inflammation osteoporosis product fosamax treatment prevention ofosteoporosis respiratory product singulair leukotriene receptor antagonist vaccinesbiological varivax merck co inc annual report table content live virus vaccine prevention chickenpox mmr ii pediatric vaccine measle mump rubella recombivax hb hepatitis b vaccine recombinant largestselle antibacterialantifungal product include primaxin cancida recently launch invanz ophthalmological cosopt trusopt largestselling urology product proscar treatment symptomatic benign prostate enlargement hiv product include crixivan protease inhibitor treatment human immunodeficiency viral infection adult primarily include sale human pharmaceutical net rebate discount pharmaceutical animal health supply sale company joint venture astrazeneca lp azlp prilosec nexium significant medco health primarily include medco health sale nonmerck product medco health pharmacy benefit service principally sale prescription drug manage prescription drug program service provide program help client control cost enhance quality prescription drug benefit member merck sell human health product primarily drug wholesaler retailer hospital clinic government agency manage health care provider health maintenance organization institution companys professional representative communicate effectiveness safety value product health care professional private practice group practice manage care organization competition health care environment market company conduct business highly competitive highly regulated global effort health care cost containment continue exert pressure product pricing access united states company work private government employer slow increase health care cost demonstrate company medicine help save cost area price flexibly product portfolio encourage grow use medicine helped offset effect increase cost pressure legislative body continue work expand health care access reduce associated cost initiative include prescription drug benefit proposal medicare beneficiary introduce congress outside united states difficult environment encumber government cost containment action company work payer help allocate scarce resource optimize health care outcome limit potentially detrimental effect government action sale growth addition country european union eu recognize economic importance researchbase pharmaceutical industry value innovative medicine society work industry representative european commission proposal complete single market pharmaceutical improve competitive climate variety mean include market deregulation increase focus privacy issue country world include united states eu united states federal state government pursue legislative regulatory initiative patient privacy include recently issue federal privacy regulation concern health information affect company operation particularly medco health predict outcome legislative regulatory advocacy initiative position respond evolve health care environment market force anticipate worldwide trend costcontainment continue result ongoing pressure health care budget continue successfully launch new product contribute health care debate monitor reform new product policy strategy enable maintain strong position change economic environment business strategy company discover new innovative product develop new indication exist productsthe result continue commitment research enhance product portfolio company continue pursue external alliance earlystage latestage product opportunity include joint venture target acquisition additionally achievement productivity gain permanent strategy productivity initiative include manufacture level optimize plant utilization implement lowestcost process improve technology transfer research manufacturing company reduce cost purchase material service reengineere core administrative process streamline organization manufacturing level company expect productivity gain continue substantially offset inflation product cost core pharmaceutical business company commit improve access medicine enhance quality life people world merck african comprehensive hivaids partnership botswana collaboration government botswana bill melinda gates foundation strive develop comprehensive sustainable approach hiv prevention care treatment catalyze access hiv medicine develop country october company announce new mg tablet formulation antiretroviral medicine stocrin introduce price merck co inc annual report table content dollar day develop country hard hit hivaids epidemic action merck work partner public private sector alike focus real barrier access medicine develop world need sustainable financing increase international assistance additional investment education training health infrastructure capacity develop country merck acquire medco containment services inc rename merckmedco later medco health medco health provide pharmacy benefit services united states home delivery pharmacie national network retail pharmacy medco health provide sophisticated program service client member pharmacy benefit plan physician pharmacy member use medco health program service help client control cost enhance quality prescription drug benefit offer member medco health client include blue crossblue shield plan manage care organization insurance carrier thirdparty benefit plan administrator employer federal state local government agency unionsponsore benefit plan january company announce plan establish medco health separate publiclytrade company medco health convert limited liability company delaware corporation change merckmedco manage care llc medco health solutions inc july company announce solely market condition postpone initial public offering ipo share medco health withdraw associate equity registration statement merck remain fully commit establishment medco health separate publiclytraded company intend complete separation mid subject market condition january company wholly own subsidiary msd japan co ltd launch tender offer acquire estimate aggregate purchase price billion remain common share banyu pharmaceutical co ltd banyu tender offer close march conditional company receive million common share bring share ownership banyu approximately company plans fund transaction cash hand japan world second large pharmaceutical market joint ventures equity method affiliate expand research base realize synergy combine capability opportunity asset company form number joint ventures merck enter agreement astra ab astra develop market astra product royaltybeare license company total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form november develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining merck astra complete restructure ownership operation joint venture company acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical lp partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca lp azlp astras merger zeneca group plc astrazeneca merger exclusive distributor product kbi retain right maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn certain partnership return ongoing revenue base sale current future kbi product partnership return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent merck share undistribute azlp gaap earning return record equity income affiliate aggregate million million million respectively astrazeneca merger trigger partial redemption merck limited partner interest redemption azlp distribute kbi base primarily multiple merck annual revenue derive sale astra usa inc product year prior redemption limited partner share agree value merck co inc annual report table content conjunction restructure payment million astra purchase option asset option buy merck interest kbi product exclude gastrointestinal medicine prilosec nexium asset option exercisable exercise price equal net present value march project future pretax revenue receive company kbi product appraise value merck right require astra purchase interest appraise value addition company grant astra option buy merck common stock interest kbi exercise price base net present value estimate future net sale prilosec nexium option exercisable year astra purchase merck interest kbi product astrazeneca merger constitute trigger event kbi restructuring agreement result merger exchange merck relinquishment right future astra product exist pende patent time merger astra pay million advance payment subject trueup calculation require repayment portion trueup directly dependent fair market value astra product right retain company accordingly recognition contingent income defer realizable determinable anticipate prior provision kbi restructuring agreement trigger event occur sum limit partner share agree value appraise value trueup guarantee minimum billion distribution limited partner share agree value payment trueup occur astrazenecas purchase mercks interest kbi product contingent exercise merck option astrazenecas option payment appraise value occur merck form joint venture johnson johnson develop market broad range nonprescription medicine consumer own joint venture expand europe canada sale joint venture product follow million gastrointestinal product product merck pasteur mrieux connaught aventis pasteur establish own joint venture market vaccine europe collaborate development combination vaccine distribution europe sale joint venture product follow million hepatitis vaccine viral vaccine vaccine merck rhnepoulenc aventis combine animal health poultry genetic business form merial limited merial fully integrate animal health company standalone joint venture equally own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie sale joint venture product follow million fipronil product avermectin product product company scheringplough corporation scheringplough enter agreement create separate equally own partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area december cholesterolmanagement partnership agreement expand include country world exclude japan october ezetimibe new class cholesterollowere agent approve zetiaand germany ezetrol partnership pursue development marketing zetia oncedaily combination tablet zocor sale ezetimibe total million january merckscheringplough pharmaceutical report result phase iii clinical trial fix combination tablet contain singulair claritin scheringplough nonsedate antihistamine demonstrate sufficient add benefit treatment seasonal allergic rhinitis merck co inc annual report table content foreign operation company operation outside united states conduct primarily subsidiarie sale merck human health product subsidiary outside united states merck human health sale respectively company worldwide business subject risk currency fluctuation governmental action company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition recent year merck expand operation country locate latin america middle east africa eastern europe asia pacific change government policy economic condition make possible merck earn fair return business develop area stable offer important opportunity growth time operating result total sale increase total volume basis foreign exchange essentially effect sale growth total sale increase total volume basis foreign exchange point unfavorable effect sale growth sale merck human health product grow foreign exchange rate half point unfavorable effect sale growth price change essentially effect sale growth measure effect change value foreign currency calculate net price increase traditionally hyperinflationary country principally latin america domestic human health sale decline reflect impact product affect patent expiration wholesaler purchasing behavior affect quarterly sale level certain product estimate net impact wholesaler buy pattern yearonyear change aggregate domestic sale minimal foreign sale grow include percentage point unfavorable effect exchange merck key human health product zocor vioxx fosamax cozaar hyzaar singulair represent twothird worldwide human health sale collectively increase sale new product cancida invanz experienced unit volume gain mature product maxalt cosopt sale product affect patent expiration include vasotec vaseretic prinivil prinzide pepcid mevacor decline billion total merck consolidated sale growth reflect impact medco health sale increase zocor merck cholesterolmodifye medicine continue solid performance worldwide sale billion increase exclude estimate impact wholesaler buy pattern yearonyear growth zocor approximate worldwide sale zocor expect approximate billion billion zocor lose basic patent protection canada certain country europe include united kingdom germany company expect decline zocor sale countrieszocor continue remain therapy choice physician prove ability clinical trial act favorably key lipid parameterslowere bad ldl cholesterol triglyceride raise level good hdl cholesterol clinical trial demonstrate zocor wellestablishe safety tolerability profile result landmark heart protection study hps largestever study cholesterolmodifye medicine show zocor mg prove save life reduce risk heart attack stroke broad range highrisk patient include people heart disease people diabete regardless cholesterol level supplemental new drug application snda file quarter merck co inc annual report table content food drug administration fda incorporate datum hps label zocor update federal guideline report people diabete increase risk cardiovascular disease increase number people united states eligible statin therapy additional million vioxx merck onceaday coxib remain large prescribed arthritis pain medication market worldwide include europe canada latin america year vioxx sale grew achieve billion sale exclude estimate impact wholesaler buy pattern yearonyear growth vioxx approximate worldwide sale coxibs vioxx arcoxia expect approximate billion billion pain relief gastrointestinal gi safety remain important consideration physician choose medication treatment arthritis gi outcomes data landmark patient vioxx gastrointestinal outcome research vigor study add labeling vioxx number key manage care account vioxx advantaged position coxibs continues grow million people exclusive prefer access vioxx manage care plan update analysis combine data clinical trial arthritis patient present american college rheumatology fourth quarter underscores prove gi safety profile vioxx new datum show vioxx significantly reduce percent incidence confirm uppergi perforation ulcer bleed compare widely non selective nonsteroidal antiinflammatory drug nsaid analysis consistent significant reduction clinically important gi event versus naproxen see vigor study clinical study acute pain vioxx demonstrate superior efficacy codeine mg acetaminophen mg oxycodone mg acetaminophen mg france refer coxibs market currently regulatory review cpmp european scientific regulatory agency discuss gastrointestinal cardiovascular safety coxib class transparency commission responsible pricing reimbursement france seek evaluate medical benefit currently market coxibs versus traditional nsaid merck new coxib arcoxia launch country include europe latin america asiapacific region arcoxia study broad range indication include osteoarthritis adult rheumatoid arthritis chronic pain acute pain dysmenorrhea menstrual pain acute gouty arthritis company announce june plan refile expand new drug application nda arcoxia fda second half company plan seek indication ankylose spondylitis chronic autoimmune disease primarily involve spine osteoarthritis rheumatoid arthritis chronic pain dysmenorrhea acute gouty arthritis enhance file broad range acute pain indication merck provide datum nda ongoing study arcoxia acute pain response fda request expand nda include additional cardiovascular safety datum arcoxia versus nonnaproxen nsaid merck conduct large clinical trial obtain cardiovascular safety datum investigational study release october american college rheumatology arcoxia mg mg daily show positive result compare placebo treat ankylose spondylitis posthoc analysis datum study arcoxia daily provide improved pain relief compare naproxen mg twice daily week december result study patient acute gouty arthritis show arcoxia mg daily provide comparable degree pain relief indomethacin mg time daily completion european union mutual recognition procedure exclude france germany arcoxia receive medical clearance remain european country oncedaily treatment osteoarthritis rheumatoid arthritis acute gouty arthritis fosamax lead product worldwide treatment prevention postmenopausal male glucocorticoidinduce osteoporosis continue strong growth sale billion increase estimate net impact wholesaler buy pattern yearonyear fosamax sale growth minimal worldwide sale fosamax expect approximate billion billion fosamax weekly launch market worldwide continue drive growth large undertreated osteoporosis market world million postmenopausal woman osteoporosis worldwide percent currently diagnose treat study fosamax present annual meeting american society bone mineral research september show tenyear period fosamax provide continuous increase lumbar spine bone mass second study headto head study bisphosphonate show european patient fosamax mg weekly increase lumbar spine hip bone mineral density bmd risedronate mg daily european dose regimen cozaar companion agent hyzaar combination cozaar diuretic hydrochlorothiazide prescribed angiotensin ii antagonist aiia worldwide treatment hypertension global sale product strong reach billion increase exclude estimate impact wholesaler buy pattern yearonyear growth cozaar hyzaar approximate worldwide sale cozaar hyzaar expect approximate billion billion cozaar experience new growth major market outside united states base result losartan intervention endpoint reduction hypertension life study announce early year life study use cozaar significantly merck co inc annual report table content reduce combined risk cardiovascular morbidity mortality notably stroke patient hypertension leave ventricular hypertrophy lvh compare betablocker atenolol analysis treatment effect ethnicity black patient treat atenolol low risk experience cardiovascular death heart attack stroke compare patient treat cozaar drug lower blood pressure similar degree merck submit supplemental nda cozaar base result life study september fda approve cozaar reduce rate progression nephropathy kidney disease type diabetic patient hypertension nephropathy new indication base reduction endpoint noninsulin dependent diabetes mellitus angiotensin ii antagonist losartan renaal study show cozaar effect overall mortality significantly delay progression endstage renal disease esrd condition require dialysis kidney transplantation survival merck ei du pont de nemour company dupont begin share equally operate profit cozaar hyzaar north america term license agreement establish party financial term outside north america change singulair merck onceaday leukotriene receptor antagonist continue strong performance asthma controller total sale singulair billion increase exclude estimate impact wholesaler buy pattern yearonyear growth singulair approximate worldwide sale singulair expect approximate billion billion singulair prescribed asthma controller allergist pediatricians united states launch million prescription singulair dispense patient positive result major european trial involve singulair present european respiratory society meeting stockholm september european study show singulair dose onceaday take inhale corticosteroid ics budesonide dose mg day effective control asthma budesonide double dose mg day measure morning peak flow rate measure lung function december fda approve singulair relief symptom seasonal allergic rhinitis know hay fever adult child young year age currently available oral allergy medication work block histamine cause allergy symptom singulair new different way treat seasonal allergy block leukotriene instead block histamine convenient onceaday tablet singulair help relieve broad range seasonal allergy symptom hour sale growth benefit cancidas new class antifungal call echinocandin glucan synthesis inhibitor introduce decade cancida treat certain lifethreatening fungal infection prevalent number people compromise immune system increase new medicine indicate treatment candidemia bloodstream infection follow candida infection intraabdominal abscess peritonitis infection line abdominal cavity pleural space infection infection lining lung indicate esophageal candidiasis invasive aspergillosis patient respond tolerate antifungal therapy amphotericin b lipid formulation amphotericin b andor itraconazole product experience growth include maxalt treatment acute migraine headache adult cosopt treat glaucoma recently launch invanz treatment select moderate severe infection adult crixivan contribute sale decline unit volume therapeutic competition supply sale prilosec nexium azlp contribute sale total supply sale azlp expect decline midsingle digit percentage rate october merckscheringplough pharmaceutical announce fda approval zetia ezetimibe new class cholesterollowere agent inhibit intestinal absorption cholesterol oncedaily tablet zetia mg approve use statin reduce ldl cholesterol total cholesterol patient high cholesterol clinical trial zetia show significant additional reduction ldl cholesterol add dose statin generally tolerate overall effect profile similar statin initial launch performance united states strong prescription write approval zetia support pivotal phase iii study evaluate efficacy safety zetia use patient high cholesterol marketing approval receive october germany brand ezetrol use market statin treatment elevate cholesterol level approval ezetimibe germany represent step seek marketing approval eu mutual recognition procedure company record interest merckscheringplough partnership equity income affiliate sale merck human health product grow foreign exchange rate percentage point unfavorable effect sale growth price change half point favorable effect growth domestic sale growth foreign sale grow include seven percentage point unfavorable effect exchange unit volume growth sale merck human health product drive key product zocor vioxx cozaarhyzaar fosamax singulair contribute merck human health volume growth proscar maxalt cancidas merck co inc annual report table content cost expense million change change material production marketing administrative research development equity income affiliate income expense net material production cost increase compare sale growth rate exclude effect exchange inflation cost increase point high unit sale volume growth high growth rate cost sale volume growth primarily attributable significant growth medco health historically lowermargin business material production cost increase compare sale growth rate primarily attributable growth lowermargin medco health business exclude effect exchange inflation cost increase point high unit sale volume growth gross margin compare gross margin reduction reflect growth medco health business effect product mix core pharmaceutical business company expect manufacture productivity offset inflation product cost core pharmaceutical business marketing administrative expense decrease total volume basis marketing administrative spending reflect impact sale force expansion launch cost support new product introduction new indication saving operationalefficiency work redesign initiative reduce company overall cost structure marketing administrative expense estimate grow midsingle digit percentage rate fullyear expense marketing administrative expense increase total essentially level volume basis include point decrease attributable marketing expense reflect success operational efficiency initiative increase resource commitment merck key growth driver market administrative expense percentage sale continuous improvement ratio primarily reflect low growth marketing administrative cost relative medco health sale growth sustain impact operational efficiency initiative research development expense increase exclude effect exchange inflation expense increase research development reflect increase investment later stage product continue significant investment basic research increase strategic spending outside licensing effort research development expense increase exclude effect exchange inflation expense increase research development pharmaceutical industry inherently longterm process follow datum unbroken trend yeartoyear increase company research development spending period compound annual growth rate research development research development expense estimate grow percent year expense equity income affiliate reflect favorable performance company joint venture partnership return azlp decrease equity income affiliate primarily reflect impact company share launch expense zetia ongoing research development expense associate merckscheringplough merck co inc annual report table content partnership contribution collaboration continue negative sale ezetimibe offset launch expense product ongoing research development spending decrease equity income affiliate primarily reflect impact company share research development expense associate merckscheringplough partnership decrease expense net reflect decrease amortization expense result implementation financial accounting standard board statement goodwill intangible fas goodwill long amortize low minority interest expense loss investment decrease expense net primarily attributable high interest income low minority interest expense increase gain sale investment decrease partially offset low exchange gain result translation company balance sheet effect income record settlement dispute proceed relate astrazeneca merger earning million share amount change change net income sale average total asset earning common share assume dilution company effective income tax rate consolidate effective income tax rate estimate approximately net income low net income net income percentage sale compare decline ratio principally high growth rate medco health historically lowermargin business offset low growth marketing administrative expense foreign currency exchange percentage point unfavorable effect growth rate compare percentage point unfavorable effect net income percentage average total asset earning common share assume dilution level grow net income earning common share assume dilution reflect benefit implementation fas favorable growth rate earning common share assume dilution compare net income result treasury stock purchase company anticipate fullyear consolidated earning common share assume dilution reflect expectation double digit earning share growth core pharmaceutical business standalone basis include year net income medco health company intention separate medco health business mid subject market condition remain unchanged separation occur company adjust consolidated earning expectation reflect separation appropriate follow supplemental information discussion represent core pharmaceutical business standalone summarize operating result merck exclude medco health standalone summarize operating result medco health combination historical standalone operating result merck medco health equal mercks consolidated operating result certain consolidating adjustment necessary preparation consolidate operating result associate primarily sale merck product medco health relate rebate receive medco health merck financial information include indicative consolidated operating result merck medco health future medco health separate company period present statement financial accounting standard accounting impairment disposal longlive asset fas effective company january preclude report business distribute stockholder discontinue operation disposal date merck co inc annual report table content merck co inc core pharmaceutical business standalone basis million sale material production income taxis net income sale merck core pharmaceutical business standalone basis grow gross margin compared decrease primarily attributable effect change product mix net income percentage sale compare reflect gross margin reduction continue investment research development medco health standalone basis million total net revenue total cost revenue income taxis net income medco health continue deliver strong sale growth net revenue report standalone basis reach billion increase medco health manage million prescription year net revenue increase primarily reflect increase price charge manufacturer increase representation new high cost drug brand prescription base high prescription drug utilization medco healths home delivery service large pharmacy benefit management pbm industry continue expand medco health home delivery prescription year grow million represent percent medco health total prescription volume medco health experience percent increase number prescription process member website wwwmedcohealthcom prescription volume million medco health provide pbm service united health group large client fiveyear contract revenues united health group represent approximately medco health net revenue total billion billion respectively medco health gross margin respectively decrease margin reflect impact competitive pricing pressure reduce discount pharmaceutical manufacturer operate cost result new business initiate begin accordance fas medco health income taxis net income reflect goodwill amortization total million medco health net income standalone basis estimate grow percent percent fullyear drive primarily increase use generic home delivery automation capital environmental expenditure capital expenditure billion billion expenditure unite states billion billion expenditure include million production facility million research development facility million environmental project million administrative safety general site project capital expenditure approve spend december billion capital expenditure estimate billion company believe compliance material respect applicable environmental law regulation capital expenditure environmental protection forecast exceed million year addition company operating maintenance expenditure pollution control approximately million expenditure purpose year forecast approximate million expenditure remediation environmental liability million estimate million year depreciation billion billion million million respectively apply location united states merck co inc annual report table content analysis liquidity capital resource net cash provide operating activity billion cash provide operation continue company primary source fund finance operating need capital expenditure cash fund capital expenditure billion pay company dividend billion partially fund purchase treasury share december total worldwide cash investment billion include billion cash cash equivalent shortterm investment billion longterm investment total include billion cash investment hold banyu select datum millions work capital total debt total liability equity cash provide operation total debt work capital level adequate meet operating requirement company ratio total debt total liability equity cash provide operation total debt reflect strength company operate cash flow ability company cover contractual obligation companys contractual obligation december follow payment period million total loan payable current portion longterm debt longterm debt operating lease loan payable current portion longterm debt include million note final maturity annual basis repurchase holder option remarkete agent remarkete redeem company loan payable current portion longterm debt reflect million longdate note subject repayment option holder annual basis december billion variable rate prefer unit issue whollyowne subsidiary redeemable option holder beginning include minority interest company billion shelf registration statement file securities exchange commission issuance debt security effective company issue million variable rate note shelf february company issue million tenyear note million variable rate note shelf remain capacity company shelf registration statement billion company strong financial position evidence triplea credit rating moodys standard poor outstanding debt issue provide high degree flexibility obtain fund competitive term ability finance ongoing operation primarily internally generate fund desirable high risk inherent research development require develop market innovative new product highly competitive nature pharmaceutical industry company participate balance sheet arrangement involve unconsolidated subsidiary provide material source finance potentially expose company material unrecorded financial obligation february board director approve purchase billion merck share july board director approve purchase time additional billion merck share company purchase billion treasury share previously authorize complete program billion program total treasury stock purchase billion period company purchase million share total cost billion dollar functional currency company foreign subsidiary significant portion company revenue denominate foreign currency merck rely sustain cash flow generate foreign source support longterm commitment dollarbase research development extent dollar value cash flow diminish result astrengthene dollar company ability fund research dollarbase strategic initiative consistent level impair company establish revenue hedge balance sheet risk management program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company partially hedge anticipate party sale expect occur planning cycle typically year future company layer hedge time increase portion sale hedge get close expect date transaction probable hedge transaction occur portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange merck co inc annual report table content rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged risk manner merck manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow fully offset decline expect future dollar cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase value anticipate foreign currency cash flow weak dollar result net benefit market value company hedge decline million million respectively uniform weaken dollar december market value determine foreign exchange option pricing model hold factor exchange rate constant merck use purchase local currency option uniform weaken dollar yield large overall potential loss market value option sensitivity measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar year program reduce volatility cash flow mitigate loss value cash flow period relative strength dollar portion revenue hedge cash flow contract report operating activity consolidate statement cash flow primary objective balance sheet risk management program protect dollar value foreign currency denominate net monetary asset effect volatility foreign exchange occur prior conversion dollar merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange dollar cash flow derive net asset merck routinely enter contract fully offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract limit basis deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate company minimize effect exchange monetary asset liability manage operating activity net asset position local level company use forward contract hedge change fair value certain foreign currency denominate availableforsale security attributable fluctuation foreign currency exchange rate sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly strengthen currency exposure company december income taxis decline million million respectively merck net long position relative major foreign currency consideration forward contract uniform strengthen dollar yield large overall potential net loss earning exchange measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow addition revenue hedge balance sheet risk management program company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk company party million notional payfloate receivefixe interest rate swap contract designate hedge fair value change million fiveyear threeyear fix rate note attributable change benchmark libor swap rate swap effectively convert fix rate obligation float rate instrument company party seven year combine interest rate currency swap contract enter convert variable rate foreign currency denominate investment variable rate dollar investment swap contract hedge change fair value investment attributable fluctuation exchange rate allow company receive variable rate return cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment market value significantly impact change interest rate market value company medium longterm fix rate investment modestly impact change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value company investment debt merck co inc annual report table content relate swap contract change interest rate indicate percentage point increase interest rate december positively impact net aggregate market value instrument million million respectively percentage point decrease december negatively impact net aggregate market value million million respectively increase sensitivity company aggregate investment debt portfolio december reflect decrease weight average maturity company investment fair value company debt determine pricing model reflect percentage point shift appropriate yield curve fair value company investment determine combination pricing duration model duration linear approximation work modest change yield generate symmetrical result pricing model reflect convexity priceyield relationship provide great precision reflect asymmetry price movement interest rate change opposite direction impact convexity pronounce longerterm maturity low interest rate environment recently issue accounting standard july financial accounting standard board fasb issue statement accounting cost associate exit disposal activity fas effective exit disposal activity initiate december adoption fas require company recognize cost associate exit disposal activity incur date commitment exit disposal plan impact company financial position result operation november fasb issue interpretation guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness fin fin require liability record guarantor balance sheet fair value issuance guarantee recognition provision fin effective guarantee issue modify december adoption fin impact company financial position result operation january fasb issue interpretation consolidation variable interest entity fin fin require variable interest entity vie consolidated company subject majority risk loss vie activity entitle receive majority entitys residual return consolidation requirement newlycreate vie transitional disclosure provision fin effective company immediately adoption fin impact company financial position result operation critical accounting policy matter consolidated financial statement include certain amount base management good estimate judgment estimate determine item provision rebate discount return income taxis depreciable amortizable life pension postretirement benefit plan assumption amount record contingency environmental liability reserve uncertainty inherent estimate actual result differ estimate company aware reasonably likely event circumstance result different amount report material impact result operation financial condition application follow accounting policy result accounting estimate potential significant impact financial statement revenue recognition merck revenues sales merck human health product recognize shipment product revenue record net provision rebate discount return establish time sale accrual rebate discount cover discount result sale merck customer intermediary wholesale purchaser rebate owe base contractual agreement legal requirement benefit provider include medicaid final dispense product pharmacy benefit plan participant accrual estimate time sale base available information portion sale rebate discount earn adjust appropriate specific know event reflect prevail contractual discount rate amount accrue rebate discount adjust trend significant event indicate adjustment appropriate accrual adjust reflect actual amount pay credit validation claim datum adjustment material result operation medco health medco health revenue consist principally sale prescription drug manage prescription drug program home delivery pharmacie network contractually affiliate retail pharmacy revenue recognize prescription dispense home delivery pharmacy retail pharmacy contractually affiliate network medco health responsibilitie client contract adjudicate member claim properly control client drug spend separate contractual pricing relationship responsibilitie retail pharmacy network interaction member indicator qualify medco health principal indicator set forth emerge issue task force issue report gross revenue principal vs net agent eitf transaction customer medco health responsibility merck co inc annual report table content client contract include validate patient member client plan prescription drug applicable formulary instruct pharmacist prescription price copayment patient identify possible adverse drug interaction pharmacist address physician prior dispense suggest medically appropriate generic alternative control drug cost client member approve prescription dispense revenue recognize medco healths home delivery pharmacie retail network contract principal gross reporting basis accordance eitf prescription price ingredient cost plus dispense fee negotiate client include portion price settle directly member copayment plus medco health administrative fee medco health credit risk respect retail copayment indicator gross treatment present addition copayment view mechanism medco health negotiate client help manage retain prescription drug spending cost level copayment affect medco health rebate margin transaction retail copayment include medco health revenue cost revenue total billion billion billion respectively term contract nature medco healths involvement prescription fulfillment process qualify principal eitf revenue transaction consist administrative fee pay medco health client medco health deduct revenue manufacturers rebate pay client client earn rebate medco health estimate rebate periodend base actual estimate claim datum estimate portion claim client earn rebate medco health basis estimate well available datum periodend recent history factor affect rebate client medco health adjust rebate payable client actual amount pay rebate pay generally quarterly basis significant event occur medco health record cumulative effect adjustment revenue identify adjust estimate prospectively consider recur matter adjustment generally result contract change client difference estimate actual product mix subject rebate product include applicable formulary adjustment material result operation medco health deduct revenue discount offer payment client payment include example implementation allowance payment risk sharing agreement client payment relate performance guarantee medco health provide implementation allowance client contract initiation capitalize payment amortize revenue life contract payment refundable cancellation relate noncancelable contract limited instance medco health enter riskshare agreement agrees share risk client drug trend increase certain level medco health determine regular basis potential deduction revenue compare client increase drug spending period specify contractual index target rate client rate increase exceed target medco health calculate deduction revenue accordance term contract contractual cap liability medco health manage risk type arrangement restrict number client contract include risk sharing cap responsibility provision require client implement drug cost management program accordingly medco health exposure riskshare arrangement material financial position liquidity rebate receivable pharmaceutical manufacturer earn base dispense prescription home delivery pharmacy pharmacy medco health retail network record reduction medco health cost revenue include account receivable medco health accrue rebate receivable multiplying estimate rebatable prescription drug dispense home delivery pharmacy dispense pharmacy retail network contractually agree manufacturer rebate medco health revise rebate receivable estimate actual difference record cost revenue final rebatable prescription calculate rebate bill manufacturer generally day subsequent end applicable quarter historically effect adjustment result reconciliation rebate recognize record actual amount bill material result operation rebate earn medco health pharmaceutical manufacturer exclude merck total billion billion billion respectively rebate receive medco health merck accordingly eliminate consolidation approximate million million million respectively rebate payable client estimate accrue concurrently rebate receivable rebate pay client base actual drug spend quarterly basis collection rebate receivable manufacturer time rebate payable revised reflect amount typically medco health client contract client right audit calculation rebate owe client date adjustment relate client audits material merck co inc annual report table content pension postretirement benefit plan net pension postretirement benefit cost total million million pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate annually modify reflect prevail market rate december portfolio highquality aa fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come december company change discount rate pension postretirement benefit plan expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum historical actual return company plan asset reference information company develop forwardlooke return expectation asset category weight average expect longterm rate return target portfolio allocate investment category result analysis company change expect rate return pension postretirement benefit plan target investment portfolio company pension plan allocate equity international equity fix income investment real estate cash investment portfolio equity weighting consistent longterm nature plans benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation december cash component actual investment portfolio slightly excess target allocation excess subsequently reinveste accord target allocation hold assumption constant net pension postretirement benefit cost company plan expect increase approximately million approximately million attributable low discount rate approximately million attributable low expect rate return actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact net pension postretirement benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact net pension postretirement benefit cost company expect minimum pension funding requirement internal revenue code precede hypothetical change discount rate expect rate return assumption impact company funding requirement unrecognize net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption expect return base calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return recognize marketrelated value asset ratably fiveyear period total unrecognized net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee amortization total unrecognized net loss companys plan december expect increase net pension postretirement benefit cost approximately million grow million contingency environmental liability merck company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable company include medco health party number antitrust suit certain certify class action institute nation retail pharmacy consumer state allege conspiracy restraint trade challenge pricing andor purchasing practice company medco health respectively significant number pharmaceutical company wholesaler sue similar litigation action action pende state court consolidate pretrial purpose united states district merck co inc annual report table content court northern district illinois company defendant finalize agreement settle federal class action allege conspiracy represent single large group retail pharmacy claim time company enter settlement satisfactory term october judicial panel multidistrict litigation panel determine consolidated pretrial proceeding federal district court chicago substantially complete panel order federal antitrust conspiracy case settle company return federal district court case originally file case return court transfer federal court brooklyn new york proceeding company engage conspiracy admission wrongdoing include settlement agreement feasible predict final outcome remain proceeding opinion company proceeding ultimately result liability material adverse effect company financial position result operation liquidity previously disclose merck advise department justice investigate marketing selling activity merck pharmaceutical manufacturer merck work government respond appropriately informational request company join ongoing litigation allege manipulation pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level judicial panel multidistrict litigation order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidated class action complaint aggregate claim previously file federal district court action expand number manufacturer include like merck defendant prior pende case company motion dismiss case pende court boston addition merck thirty pharmaceutical manufacturer recently name similar complaint file federal court new york new york county suffolk company believe lawsuit completely merit vigorously defend january department justice notify federal court new orleans louisiana go intervene pende federal false claim act case file seal december company court issue order unseal complaint file physician louisiana ordered complaint serve complaint allege merck discount pepcid certain louisiana hospital lead increase cost medicaid merck believe complaint completely merit vigorously defend previously report dispute merck pharmacia corporation pharmacia compete claim patent right class compound include rofecoxib active ingredient vioxx settle worldwide basis party result company maintain worldwide exclusive patent right vioxx number federal state lawsuit involve individual claim purport class action file company respect vioxx lawsuit defendant pfizer inc pharmacia market compete product lawsuit include allegation gastrointestinal bleed cardiovascular event company believe lawsuit completely merit vigorously defend company party claim bring consumer protection act united kingdom allege certain child suffer variety condition result vaccinate bivalent vaccine measle rubella trivalent vaccine measle mump rubella include company mmr ii pharmaceutical company sue claimant allege adverse consequence include autism inflammatory bowel disease epilepsy diabete encephalitis encephalopathy chronic fatigue syndrome lead case select trial schedule commence april merck company trial case initially limit issue causation defect condition autistic spectrum disorder inflammatory bowel disease company believe lawsuit completely merit vigorously defend company party individual class action product liability lawsuit claim united states involve pediatric vaccine ie hepatitis b vaccine haemophilus influenza type b vaccine contain thimerosal preservative vaccine defendant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result thimerosal introduce develop body company successful case dismiss stay ground national vaccine injury compensation program nvicp prohibit person file maintain civil action seek damage vaccine merck co inc annual report table content manufacturer vaccinerelate injury petition file united states court federal claim number similar case mmr ii andor thimerosalcontaining vaccine file united states court federal claim nvicp procedure process case contemplate decision general causation issue july company believe lawsuit claim completely merit vigorously defend proceeding party time time generic manufacturers pharmaceutical product file abbreviate new drug application anda fda seek market generic form company product prior expiration relevant patent own company generic pharmaceutical manufacturer submit andas fda seek market generic form fosamax alendronate prilosec omeprazole prior expiration company astrazenecas case prilosec patent concern product generic company anda include allegation noninfringement invalidity unenforceability patent generic manufacturer receive fda approval market generic form prilosec company file patent infringement suit federal court company file andas generic alendronate astrazeneca company file patent infringement suit federal court company file andas generic omeprazole case alendronate similar patent challenge exist certain foreign jurisdiction company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity product trial respect alendronate daily product conclude november november decision issue district court delaware find company patent valid infringe appeal file defendant trial involve alendronate weekly product schedule commence march january high court justice england wale hold patent company protect alendronate daily weekly product invalid united kingdom company proceed appeal decision case omeprazole trial court united states render opinion october uphold validity company astrazenecas patent cover stabilize formulation omeprazole rule defendant omeprazole product infringe patent defendant product find infringe formulation patent appeal file party trial respect certain generic manufacturer omeprazole product trial date set previously disclose company name defendant number purport class action lawsuit shareholder derivative action relate company revenue recognition practice retail copayment pay individual medco health provide pharmaceutical benefit current member management member board director name defendant certain lawsuit company believe lawsuit completely merit vigorously defend company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust feasibility study relate cost assessment remedial technique complete extent potentially responsible party prps jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify provide cost worldwide survey initially perform assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate estimate extent contamination site initially preinvestigation stage liability potential cost remediation accrue time definitive information available course investigation andor remedial effort site estimate refined accrual adjust accordingly estimate related accrual continue refine annually management opinion liability environmental matter probable reasonably estimable accrue total million million december december respectively liabilitie undiscounted consider potential recovery insurer party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year merck co inc annual report table content medco health recently company medco health agree settle class action basis series lawsuit assert violation employee retirement income security act erisa company medco health certain plaintiff counsel file settlement federal district court new york plaintiff pharmaceutical benefit plan medco health pharmacy benefit manager file case propose class action settlement agree plaintiff initial case gruer case file medco health company propose settlement court preliminarily approve company medco health agree pay million medco health agree change continue certain specify business practice period year financial compensation intend benefit member settlement class include erisa plan medco health administer pharmacy benefit time december settlement preliminarily approve class member plan opportunity participate opt settlement court schedule hearing purpose determine fairness settlement class member initial plaintiff group lawyer file additional erisa lawsuit company medco health expect oppose settlement settlement final district court grant final approval appeal resolve medco health company agree propose settlement order avoid significant cost distraction protract litigation gruer case similar claim pharmaceutical benefit manager pende case allege medco health treat fiduciary erisa medco health breach fiduciary duty benefit plan amend complaint gruer case allege company medco health violate erisa medco health increase company market share enter certain prohibit transaction favor company product plaintiff demand medco health company turn unlawfully obtain profit trust set benefit plan plaintiff indicate amend complaint medco health allege violation sherman act clayton act state antitrust law allege conspiracy suppress price competition unlawful combination allegedly result high pharmaceutical price similar complaint medco health company assert claim breach fiduciary duty erisa file additional action plan participant purportedly behalf plan action similarlysituate self fund plan class action status seek action plan decide opt participate propose settlement discuss party lawsuit amend complaint action allege activity company medco health violate federal state racketeering law addition propose class action complaint medco health company file trustee benefit plan complaint action rely theory litigation discuss lawsuit base allegation pende medco health federal court california state court new jersey theory liability action company defendant base california statute prohibit unfair business practice plaintiff purport sue behalf general public california seek injunctive relief disgorgement revenue allegedly improperly receive company medco health theory liability new jersey action base new jersey consumer protection statute plaintiff purport represent class similarlysituate non erisa plan seek compensatory treble damage new jersey court dismiss new jersey action reinitiate certain circumstance medco health company believe case completely merit medco health fiduciary mean erisa company medco health violate erisa california unfair business practice law new jersey consumer protection law medco health company intend vigorously defend remain claim previously disclose august medco health receive letter civil division united states attorney office eastern district pennsylvania relate ongoing investigation pharmacy benefit management industry letter government provide medco health preliminary assessment investigation summarize remedy government seek prove violation law company standpoint letter raise significant new issue letter government state prepare decide intervene qui tam whistleblow action pende eastern district pennsylvania medco health previously disclose government letter specifically state issue formal demand offer settle settlement recommendation medco health believe practice comply legal requirement medco health continue engage dialogue government respect matter legal proceeding involve company medco health principally product liability intellectual property suit involve company pende feasible predict outcome proceeding opinion company proceeding merck co inc annual report table content adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company medco health addition time time federal state regulator seek information practice industry company medco health operate feasible predict outcome request information company medco health expect inquiry material adverse effect financial position liquidity result operation company medco health cautionary factor affect future result annual report write report oral statement time time company contain socalle forward look statement subject risk uncertaintie identify forwardlooke statement use word expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product approval development program carefully consider statement understand factor cause actual result differ company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor describe company filing securities exchange commission especially form k q k item company annual report year end december file march company discuss detail important factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act prior filing form k year end december reference item company annual report year end december understand possible predict identify factor consequently reader consider list complete statement potential risk uncertainty dividend pay common share year th q rd q nd q st q condense interim financial datum million share amount th q rd q nd q st q sale material production cost market administrative expense research development expense equity income affiliate income expense net income taxis net income basic earning common share earning common share assume dilution sale material production cost market administrative expense research development expense equity income affiliate income expense net income taxis net income basic earning common share earning common share assume dilution common stock market price th q rd q nd q st q high low high low principal market trading common stock new york stock exchange symbol mrk merck co inc annual report table content consolidate statement income merck co inc subsidiary year end december millions share amount sale cost expense material production marketing administrative research development equity income affiliate income expense net income taxis tax income net income basic earning common share earning common share assume dilution consolidated statement retain earning merck co inc subsidiary year end december million balance january net income common stock dividend declare balance december consolidate statement comprehensive income merck co inc subsidiary year end december millions net income comprehensive income loss net unrealized loss gain derivative net tax net income realization net unrealized gain investment net tax net income realization minimum pension liability net tax comprehensive income accompany note integral consolidated financial statement merck co inc annual report table content consolidate balance sheet merck co inc subsidiary december million asset current asset cash cash equivalent shortterm investment account receivable inventory prepaid expense taxis total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress allowance depreciation goodwill intangible net asset liability stockholder equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxis noncurrent liability minority interest stockholder equity common stock cent par value authorize share issue share share paidin capital retain earning accumulate comprehensive loss income treasury stock cost share share total stockholder equity accompany note integral consolidated financial statement merck co inc annual report table content consolidate statement cash flow merck co inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity depreciation amortization defer income taxis net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity cash flow invest activity capital expenditure purchase security subsidiary investment proceed sale security subsidiarie investment net cash investing activity cash flow financing activity net change shortterm borrowing proceed issuance debt payment debt proceed issuance preferred unit subsidiary purchase treasury stock dividend pay stockholder proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent net increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement merck co inc annual report table content note consolidated financial statement merck co inc subsidiarie million share amount nature operation merck global researchdriven pharmaceutical product service company discover develop manufacture market broad range innovative product improve human animal health directly joint venture provide pharmacy benefit management service medco health solutions inc medco health human health product include therapeutic preventive agent generally sell prescription treatment human disorder pharmacy benefit service primarily include sale prescription drug manage prescription drug program service provide program manage patient health drug utilization summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain control interest determine majority ownership interest absence substantive party participate right consolidate subsidiary merck ownership outside stockholder interest show minority interest investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis foreign currency translation dollar functional currency company foreign subsidiary cash cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory substantially domestic pharmaceutical inventory value low lastin firstout lifo cost market book tax purpose medco health inventory foreign pharmaceutical inventory value low firstin firstout fifo cost market investment investment classified availableforsale report fair value unrealize gain loss extent hedge report net tax minority interest accumulate comprehensive income investment debt security classify heldto maturity consistent management intent report cost impairment loss charge income expense net thantemporary decline fair value company consider available evidence evaluate potential impairment investment include duration extent fair value cost company ability intent hold investment revenue recognition revenue sales merck human health product recognize shipment product revenue record net provision rebate discount return establish time sale medco health revenue consist principally sale prescription drug manage prescription drug program home delivery pharmacie network contractually affiliate retail pharmacy recognize prescription dispense medco health evaluate client contract indicator emerge issue task force issue report gross revenue principal vs net agent determine act principal agent fulfillment prescription retail pharmacy network medco health act principal revenue recognize gross reporting basis prescription price ingredient cost plus dispense fee negotiate client include portion price allocate client settle directly member copayment medco health separate contractual relationship client pharmacie b responsible validate economically manage claim claim adjudication process c commit set prescription price pharmacy include instruct pharmacy price settle copayment requirement manage overall prescription drug relationship patient e credit risk price client medco health adjudicate prescription pharmacy contract directly client financial risk medco health revenue record net reporting service revenue administrative fee earn medco health processing claim rebate guarantee riskshare payment pay client discount deduct revenue earn client contractual payment client generally initiation contract implementation allowance example designate client funding cost transition plan medco health compensation certain datum licensing right grant client medco health medco health consider payment integral pricing contract believe represent variability time cash flow change underlie economic contract accordingly payment capitalize amortize reduction revenue straightline basis life contract payment refundable cancellation merck co inc annual report table content contract relate noncancelable contract amount capitalize assess periodically recoverability base profitability contract medco health revenue include service revenue consist principally administrative fee earn client non product relate service revenue include sale datum pharmaceutical manufacturer health care organization administrative fee earn service comprise claim process eligibility management benefit management pharmacy network management relate customer service recognize prescription dispense nonproduct relate service revenue record medco health performance occur collectibility assure depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate method estimate useful life primarily range year building year machinery equipment office furnishing goodwill intangible goodwill represent excess acquisition cost fair value net asset business purchase effective january company adopt provision statement financial accounting standard goodwill intangible asset fas address recognition measurement goodwill intangible subsequent business combination accordance fas goodwill associate acquisition subsequent june amortize note effective january goodwill exist june amortize assign reporting unit company segment evaluate impairment annual basis fair value base test amortization expense goodwill record report net income increase million basic earning common share earning common share assume dilution million basic earning common share earning common share assume dilution respectively company complete transitional annual impairment test determine goodwill impair provision new guidance acquire intangible record cost amortize straightline basis estimate useful life note event circumstance warrant review company assess recoverability future operation intangible undiscounted cash flow derive low appropriate asset grouping generally subsidiary level impairment recognize operating result extent carry value exceed fair value determine base net present value estimate future cash flow stockbase compensation employee stockbase compensation recognize intrinsic value method generally employee stock option grant purchase share company stock fair market value time grant accordingly compensation expense recognize company stockbase compensation plan employee performancebase award option grant employee certain equity method investee total significant effect net income earning common share company apply fair value method recognize employee stockbase compensation follow year end december net income report compensation expense net tax report fas pro forma net income earning common share basica report basicpro forma assume dilutiona report assume dilutionpro forma average fair value employee nonemployee director option grant respectively fair value estimate blackschole optionprice model base weighted average market price grant date follow weight average assumption year end december dividend yield riskfree interest rate volatility expect life year use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate determine item provision rebate discount return income taxis depreciable amortizable life pension postretirement benefit plan assumption amount record contingency environmental liability reserve uncertainty inherent estimate actual result differ estimate company aware reasonably likely event circumstance result different amount report material impact result operation financial condition reclassification certain reclassification prior year amount conform current year presentation acquisition july company complete acquisition rosetta inpharmatics inc rosetta lead informational genomics company taxfree reorganization rosetta design develop unique technology efficiently analyze merck co inc annual report table content gene datum predict medical compound interact different kind cell body allow merck scientist precisely select drug target potentially accelerate development process acquisition account purchase method accordingly rosetta result operation include company acquisition date pro forma information provide transaction material impact company result operation financial position accordance agreement plan merger agreement share outstanding rosetta stock convert share merck stock result issuance company approximately million share common stock aggregate purchase price transaction approximate million include million common share value million represent employee stock option value agreement date million estimate transaction fee allocation purchase price result tangible asset million consist primarily cash shortterm investment intangible asset million liability assume million include defer tax liability million associate intangible asset goodwill total million intangible weight average useful life approximate year aggregate major class include million patent right million contractual agreement accordance fas goodwill associate rosetta acquisition amortize joint venture equity method affiliate merck enter agreement astra ab astra develop market astra product royaltybeare license company total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining merck astra complete restructure ownership operation joint venture company acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical lp partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca lp azlp astras merger zeneca group plc astrazeneca merger exclusive distributor product kbi retain right maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn certain partnership return ongoing revenue base sale current future kbi product partnership return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent merck share undistribute azlp gaap earning return record equity income affiliate aggregate million million million respectively astrazeneca merger trigger partial redemption mercks limited partnership interest redemption azlp distribute kbi base primarily multiple merck annual revenue derive sale astra usa inc product year prior redemption limited partner share agree value conjunction restructure payment million defer astra purchase option asset option buy merck interest kbi product exclude gastrointestinal medicine prilosec nexium asset option exercisable exercise price equal net present value march project future pretax revenue receive company kbi product appraise value merck right require astra purchase interest appraise value addition company grant astra option buy merck common stock interest kbi exercise price base net present value estimate future net sale prilosec nexium option exercisable year astra purchase merck interest kbi product astrazeneca merger constitute trigger event kbi restructuring agreement result merger exchange merck relinquishment right future astra product exist pende patent time merger astra pay million advance payment subject trueup calculation require repayment portion trueup directly dependent fair market value astra product right retain company accordingly recognition contingent income defer realizable determinable anticipate prior provision kbi restructuring agreement trigger event occur sum limit partner share agree value appraise value trueup guarantee minimum billion distribution limited partner share agree value payment trueup occur astrazenecas purchase mercks interest kbi product contingent exercise merck option astrazenecas option payment appraise value occur merck form joint venture johnson johnson develop market broad range nonprescription medicine consumer own venture expand europe canada sale product market joint venture million million million merck co inc annual report table content merck pasteur mrieux connaught aventis pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe joint venture vaccine sale million million million merck rhonepoulenc aventis combine animal health poultry genetic business form merial limited merial fully integrate animal health company standalone joint venture equally own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie merial sale billion billion company scheringplough corporation scheringplough enter agreement create separate equally own partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area december cholesterolmanagement partnership agreement expand include country world exclude japan october ezetimibe new class cholesterollowere agent approve zetia germany ezetrol partnership pursue development marketing zetia oncedaily combination tablet zocor sale ezetimibe total million january merckscheringplough pharmaceutical report result phase iii clinical trial fix combination tablet contain singulair claritin scheringplough nonsedate antihistamine demonstrate sufficient add benefit treatment seasonal allergic rhinitis investment affiliate account equity method include joint venture total billion december billion december amount report asset dividend distribution receive affiliate million million million financial instrument adoption financial accounting standard board statement account derivative instrument hedge activity fas january company record favorable cumulative effect accounting change million tax comprehensive income loss represent mark fair value purchase local currency option note cumulative effect accounting change record net income significant foreign currency risk management dollar functional currency company foreign subsidiary significant portion company revenue denominate foreign currency merck rely sustain cash flow generate foreign source support longterm commitment dollarbase research development extent dollar value cash flow diminish result strengthen dollar company ability fund research dollarbase strategic initiative consistent level impair company establish revenue hedge balance sheet risk management program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company partially hedge anticipate party sale expect occur planning cycle typically year future company layer hedge time increase portion sale hedge get close expect date transaction probable hedge transaction occur portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged risk manner merck manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow fully offset decline expect future dollar cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase value anticipate foreign currency cash flow month change option intrinsic value defer accumulate comprehensive income aoci recognition hedge anticipate revenue amount associate option time value exclude designate hedge relationship mark fair value earning significant effective permit fas implementation guidance finalize june designate hedge relationship base total change option cash flow accordingly entire fair value change option defer aoci reclassify sale hedge anticipate revenue recognize hedge relationship perfectly effective hedge ineffectiveness record fair value purchase currency option report account receivable asset primary objective balance sheet risk management program protect dollar value foreign currency denominate net monetary asset effect volatility foreign exchange occur prior conversion dollar merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange dollar cash flow derive netasset merck routinely enter contract fully offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract limit basis merck co inc annual report table content deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate company minimize effect exchange monetary asset liability manage operating activity net asset position local level foreign currency denominate monetary asset liability remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year company use forward contract hedge change fair value certain foreign currency denominate availableforsale security attributable fluctuation foreign currency exchange rate change fair value hedge security fluctuation spot rate offset income expense net fair value change forward contract attributable spot rate fluctuation hedge ineffectiveness material change contract fair value spotforward difference exclude designate hedge relationship recognize income expense net amount significant year end december fair value forward exchange contract report follow balance sheet line item account receivable current portion gain position asset noncurrent portion gain position accrue current liability current portion loss position defer income taxis noncurrent liability noncurrent portion loss position interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk company enter fiveyear threeyear million notional payfloate receivefixe interest rate swap contract designate hedge fair value change million fiveyear threeyear fix rate note attributable change benchmark london interbank offer rate libor swap rate swap effectively convert fix rate obligation float rate instrument fair value change note fully offset interest expense fair value change swap contract company party sevenyear combine interest rate currency swap contract enter convert variable rate foreign currency denominate investment variable rate dollar investment portion contract terminate conjunction sale portion relate asset immaterial impact net income interest rate component swap designate hedge currency swap component designate hedge change fair value investment attributable exchange accordingly change fair value investment fluctuation spot rate offset income expense net fair value change currency swap hedge ineffectiveness significant similar fiveyear swap contract mature relate asset sell immaterial impact net income june medco health enter swapbase rate lock agreement hedge benchmark interest rate associate anticipate july issuance million fiveyear tenyear fix rate note note issue concurrently subsequent completion propose initial public offering medco health share swapbase contract designate hedge variability cash flow future semiannual interest payment anticipate debt offering change libor swap benchmark interest rate period prior expect issuance loss contract maturity total approximately million end second quarter probable specific hedge forecast transaction occur month date originally specify charge income expense net fair value contract report account receivable asset accrue current liability defer income taxis noncurrent liability fair value financial instrument summarize carry value fair value companys financial instrument december fair value estimate base market price available dealer quote carry fair carry fair value value value value asset cash cash equivalent shortterm investment longterm investment purchase currency option forward exchange contract currency swap interest rate swap liabilitie loan payable current portion longterm debt longterm debt forward exchange contract merck co inc annual report table content summary carry value fair value company investment december follow carry fair carry fair value value value value availableforsale debt security equity security heldtomaturity security summary december gross unrealized gain loss companys availableforsale investment record net tax minority interest aoci follow gross unrealized gross unrealized gain loss gain loss debt security equity security availableforsale debt security heldtomaturity security mature year total billion million respectively december remain debt security billion mature year december million million respectively heldtomaturity security mature set million million respectively nontransferable note obligation issue company concentration credit risk ongoing control procedure company monitor concentration credit risk associate corporate issuer security financial institution conduct business credit risk minimal credit exposure limit establish avoid concentration single issuer institution drug wholesaler represent aggregate approximately onefifth company account receivable december company monitor creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale inventory inventory december consist finished good raw material work process supply total approximate current cost reduction lifo cost inventory value lifo method comprise approximately inventory december respectively intangible intangible december consist customer relationshipsmedco health patent product right total acquire cost customer relationshipsmedco health patent product right total accumulate amortization aggregate amortization expense record material production expense income expense net total million million million estimate aggregate amortization expense year follow million million million million million loan payable longterm debt commitment loan payable december consist primarily billion billion respectively commercial paper borrowing million note annual interest rate reset final maturity annual basis note repurchase holder option remarkete agent remarkete redeem company december loan payable reflect million million respectively longdate note subject repayment option holder annual basis weight average interest rate borrowing december respectively longterm debt december consist astra note note note euronote debenture debenture variable rate borrowing debenture december company party interest rate swap contract effectively convert fix rate note float rate instrument note december consist primarily million borrowing variable rate average respectively december million million borrowing subject repayment option holder begin respectively year consist foreign borrowing vary rate merck co inc annual report table content aggregate maturity longterm debt year follow million million billion million million rental expense company operating lease net sublease income million minimum aggregate rental commitment noncancellable lease follow million million million million million million company significant capital lease contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable company include medco health party number antitrust suit certain certify class action institute nation retail pharmacy consumer state allege conspiracy restraint trade challenge pricing andor purchasing practice company medco health respectively significant number pharmaceutical company wholesaler sue similar litigation action action pende state court consolidate pretrial purpose united states district court northern district illinois company defendant finalize agreement settle federal class action allege conspiracy represent single large group retail pharmacy claim time company enter settlement satisfactory term october judicial panel multidistrict litigation panel determine consolidated pretrial proceeding federal district court chicago substantially complete panel order federal antitrust conspiracy case settle company return federal district court case originally file case return court transfer federal court brooklyn new york proceeding company engage conspiracy admission wrongdoing include settlement agreement feasible predict final outcome remain proceeding opinion company proceeding ultimately result liability material adverse effect company financial position result operation liquidity number federal state lawsuit involve individual claim purport class action file company respect vioxx lawsuit defendant pfizer inc pharmacia corporation market compete product lawsuit include allegation gastrointestinal bleed cardiovascular event company believe lawsuit completely merit vigorously defend company party claim bring consumer protection act united kingdom allege certain child suffer variety condition result vaccinate bivalent vaccine measle rubella trivalent vaccine measle mump rubella include company mmr ii company believe lawsuit completely merit vigorously defend company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust feasibility study relate cost assessment remedial technique complete extent potentially responsible party prps jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify provide cost worldwide survey initially perform assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate estimate extent contamination site initially preinvestigation stage liability potential cost remediation accrue time definitive information available course investigation andor remedial effort site estimate refined accrual adjust accordingly estimate related accrual continue refine annually management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery insurer party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year recently company medco health agree settle class action basis series lawsuit assert violation theemployee retirement income security act erisa company medco health certain plaintiff counsel file merck co inc annual report table content settlement federal district court new york plaintiff pharmaceutical benefit plan medco health pharmacy benefit manager file case propose class action settlement agree plaintiff initial case gruer case file medco health company propose settlement court preliminarily approve company medco health agree pay million medco health agree change continue certain specify business practice period year financial compensation intend benefit member settlement class include erisa plan medco health administer pharmacy benefit time december settlement preliminarily approve class member plan opportunity participate opt settlement court schedule hearing purpose determine fairness settlement class member initial plaintiff group lawyer file additional erisa lawsuit company medco health expect oppose settlement settlement final district court grant final approval appeal resolve medco health company agree propose settlement order avoid significant cost distraction protract litigation gruer case similar claim pharmaceutical benefit manager pende case allege medco health treat fiduciary erisa medco health breach fiduciary duty benefit plan amend complaint gruer case allege company medco health violate erisa medco health increase company market share enter certain prohibit transaction favor company product plaintiff demand medco health company turn unlawfully obtain profit trust set benefit plan plaintiff indicate amend complaint medco health allege violation sherman act clayton act state antitrust law allege conspiracy suppress price competition unlawful combination allegedly result high pharmaceutical price similar complaint medco health company assert claim breach fiduciary duty erisa file additional action plan participant purportedly behalf plan action similarlysituate self fund plan class action status seek action plan decide opt participate propose settlement discuss party lawsuit amend complaint action allege activity company medco health violate federal state racketeering law addition propose class action complaint medco health company file trustee benefit plan complaint action rely theory litigation discuss lawsuit base allegation pende medco health federal court california state court new jersey theory liability action company defendant base california statute prohibit unfair business practice plaintiff purport sue behalf general public california seek injunctive relief disgorgement revenue allegedly improperly receive company medco health theory liability new jersey action base new jersey consumer protection statute plaintiff purport represent class similarlysituate non erisa plan seek compensatory treble damage new jersey court dismiss new jersey action reinitiate certain circumstance medco health company believe case completely merit medco health fiduciary mean erisa company medco health violate erisa california unfair business practice law new jersey consumer protection law medco health company intend vigorously defend remain claim legal proceeding involve company medco health principally product liability intellectual property suit involve company pende feasible predict outcome proceeding opinion company proceeding adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company medco health addition time time federal state regulator seek information practice industry company medco health operate feasible predict outcome request information company medco health expect inquiry material adverse effect financial position liquidity result operation company medco health prefer stock subsidiary company march whollyowne subsidiary company issue billion par value variable rate prefer unit unit redeemable par value plus accrue dividend option issuer time redeemable option holder march end fiveyear interval addition certain provision lead company subsidiary decide redeem preferred unit credit rating company unsecure senior debt obligation fall specify level likelihood company believe remote preferred security hold subsidiary level include minority interest consolidate financial statement connection restructure ami note company assume billion par value prefer stock obligation dividend rate annum carry kbi include minority interest small portion prefer stock carry kbi convertible kbi common share prefer security convertible company common share include common share issuable purpose compute earning common share assume dilution note stockholder equityother paidin capital increase million million million respectively merck co inc annual report table content increase include million result share issue equivalent employee stock option assume connection rosetta acquisition note remain increase primarily reflect impact share issue exercise stock option relate income tax benefit summary treasury stock transaction share millions follow share cost share cost share cost balance jan purchase issuance balance dec issue primarily stock option plan december million share prefer stock par value authorize issue stock option plan company stock option plan employee nonemployee director employee certain company equity method investee grant option purchase share company common stock fair market value time grant plan approve company shareholder option grant begin generally vest ratably year grant prior generally vest year option expire year date grant company stock option plan employee provide grant performancebase stock award connection merck acquisition rosetta medco healths acquisition provantage health services inc stock option outstanding acquisition date convert option purchase share company common stock equivalent value summarize information relative company stock option plan share thousand follow average number share price outstanding december grant exercise forfeited equivalent option assume outstanding december grant exercise forfeited equivalent option assume outstanding december grant exercise forfeit outstanding december weight average exercise price number share average price option exercisable december million share million share million share respectively december million share million share respectively available future grant term plan summarize information stock option outstanding exercisable december share thousand follow outstanding exercisable exercise price number average average number average range share life price share p rice weight average contractual life remain year weight average exercise price pension postretirement benefit plan net cost company pension plan consist follow component year end december service cost interest cost expect return plan asset net amortization net pension cost net pension cost attributable international plan include table million million million net cost postretirement benefit pension consist follow component year end december service cost interest cost expect return plan asset net amortization curtailment net postretirement benefit cost cost health care life insurance benefit active employee million million million merck co inc annual report table content summarize information change plan asset benefit obligation follow postretirement pension benefit benefit fair value plan asset january actual return plan asset company contribution benefit pay plan asset fair value plan asset december benefit obligation january service cost interest cost actuarial loss benefit pay plan amendment benefit obligation december fair value international pension plan asset include precede table billion million pension benefit obligation international plan include table billion billion reconciliation plan fund status net asset liability recognize december follow postretirement pension benefit benefit plan asset benefit obligation unrecognized net loss unrecognized plan change unrecognize transitional net asset net asset liability recognize asset accrue current liability defer income taxis noncurrent liability accumulate comprehensive loss pension plan benefit obligation excess plan asset december fair value plan asset billion billion respectively benefit obligation billion billion respectively plan accumulate benefit obligation excess plan asset december fair value plan asset million million respectively accumulate benefit obligation billion million respectively assumption determine plan information follow pension postretirement benefit december discount rate expect rate return plan asset salary growth rate company reassesse benefit plan assumption regular basis company change expect rate return hold assumption constant net pension postretirement benefit cost company plan expect increase approximately million approximately million attributable low discount rate december million attributable low expect rate return year present international pension plan assumption range discount rate expect rate return plan asset salary growth rate unrecognized net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption unrecognize net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee amortization unrecognized net loss companys plan december expect increase net pension postretirement benefit cost approximately million grow million december company minimum pension liability million million respectively represent extent accumulate benefit obligation exceed plan asset certain company pension plan increase minimum pension liability record comprehensive income loss asset primarily reflect increase benefit obligation attributable reduction discount rate assumption certain plan decrease fair value plan asset health care cost trend rate postretirement benefit plan december rate expect decline eightyear period percentage point change health care cost trend rate follow effect percentage point increase decrease effect total service interest cost component effect benefit obligation merck co inc annual report table content company change participant contribution eligibility requirement attribution methodology certain postretirement benefit plan amendment reduce benefit obligation million generate curtailment gain million income expense net year end december interest income interest expense exchange gain minority interest amortization goodwill intangible net minority interest include party share exchange gain loss arise translation financial statement dollar reduce minority interest reflect low dividend variable rate prefer unit note decrease minority interest expense associated banyu pharmaceutical co ltd banyu january company wholly own subsidiary msd japan co ltd launch tender offer acquire estimate aggregate purchase price billion remain common share banyu tender offer close march conditional company receive million common share bring share ownership banyu approximately decrease amortization goodwill intangible reflect adoption fas note interest pay million million million taxis income reconciliation company effective tax rate statutory rate follow tax rate statutory rate apply pretax income differential arise foreign earning tax exemption puerto rico operation state taxis domestic company contribute approximately consolidate pretax income taxis income consist year end december current provision federal foreign state defer provision federal foreign state defer income taxis december consist asset liability asset liability intangible inventory relate accelerated depreciation advance payment equity investment pension opeb accrue rebate compensation relate environmental relate subtotal valuation allowance total defer taxis net defer tax liability recognize prepay expense taxis asset income taxis payable deferred income taxis noncurrent liability income taxis pay billion billion billion respectively stock option exercise reduce income taxis pay million million million respectively december foreign earning billion domestic earning million retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability earning include income manufacturing operation ireland taxexempt tax addition company domestic subsidiary operate puerto rico tax incentive grant expire merck co inc annual report table content company federal income tax return audit earning share weight average common share computation basic earning common share earning common share assume dilution share million follow year end december average common share outstanding common share issuable average common share outstanding assume dilution issuable primarily stock option plan comprehensive income adoption fas january company record favorable cumulative effect accounting change million comprehensive income loss represent mark fair value purchase local currency option mature hedge anticipate foreign currency denominate sale period december million defer loss associate option mature month hedge anticipate foreign currency denominate sale period component comprehensive income loss follow pretax tax tax year end december net unrealized loss derivative net income realization derivative net unrealized gain investment net income realization investment minimum pension liability year end december cumulative effect accounting change net unrealized gain derivative net income realization derivative net unrealized gain investment net income realization investment minimum pension liability year end december net unrealize gain investment net income realization investment minimum pension liability net applicable minority interest component accumulate comprehensive loss income follow december net unrealized loss gain derivative net unrealized gain investment minimum pension liability segment reporting company operation principally manage product service basis comprise reportable segment merck pharmaceutical include product market directly joint venture medco health merck pharmaceutical product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization institution medco health revenue consist principally sale prescription drug manage prescription drug program home delivery pharmacy network contractually affiliate retail pharmacy service provide program help client control cost enhance quality prescription drug benefit offer member medco health client include blue crossblue shield plan manage care organization insurance carrier thirdparty benefit plan administrator employer federal state local government agency unionsponsore benefit plan medco health client represent approximately medco health net revenue medco health revenue follow table reflect sale prescription drug drug spend basis include amount reportable revenue consolidate statement income accordance company internal management reporting present chief operating decision maker merck co inc annual report table content include nonreportable human animal health segment revenue profit segment follow merck medco pharmaceutical health total year end december segment revenue segment profit include segment profit equity income loss affiliate depreciation amortization year end december segment revenue segment profit include segment profit equity income loss affiliate depreciation amortization year end december segment revenue segment profit include segment profit equity income loss affiliate depreciation amortization segment profit comprise segment revenue certain element material production cost operating expense include component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker company allocate vast majority indirect production cost research development expense general administrative expense predominantly relate merck pharmaceutical business cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include marketing segment profit vast majority goodwill amortization intangible amortization predominantly relate medco health business cost financing capital employ allocate internal management reporting include marketing segment profit reconciliation total segment revenue consolidate sale follow year end december segment revenue revenue adjustment revenue primarily comprise miscellaneous corporate revenue sale relate divested product business supply sale adjustment represent elimination receipt report revenue internal management report reportable revenue gaap consolidated sale include billion billion billion revenue derive united states billion billion billion revenue derive foreign operation respectively reconciliation total segment profit consolidate income taxis follow year end december segment profit profit adjustment unallocate interest income interest expense equity income loss affiliate depreciation amortization research development expense net profit primarily comprise miscellaneous corporate profit operating profit relate divested product business supply sale adjustment represent elimination effect double count certain item income expense equity income loss affiliate include taxis pay joint venture level portion equity income report segment profit expense net include expense corporate manufacturing cost center miscellaneous income expense net net property plant equipment include billion billion billion asset locate united states billion billion billion asset locate outside united states respectively company disaggregate asset product service basis internal management report information present january company announce plan establish medco health separate publiclytrade company medco health convert limited liability company delaware corporation change merckmedco manage care llc medco health solutions inc july merck announce solely market condition postpone initial public offering ipo share medco health withdraw associate equity registration statement merck remain fully commit establishment medco health separate publiclytraded company intend complete separation mid subject market condition merck co inc annual report table content management report primary responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization establish internal control management weigh cost system benefit believe system provide staff internal auditor regularly monitor adequacy application internal control worldwide basis insure personnel continue understand system internal control procedure policy concern good prudent business practice company periodically conduct management stewardship program key management financial personnel program reinforce importance understand internal control review key corporate policy procedure system addition ethical business practice program implement reinforce company longstanding commitment high ethical standard conduct business independent public accountant audit company consolidated financial statement describe report audits design purpose form opinion internal control company accounting system procedure internal control subject testing auditing procedure sufficient enable independent public accountant render opinion company financial statement recommendation internal auditor independent public accountant review management control procedure implement revise appropriate respond recommendation material control weakness bring attention management management opinion year end december internal control system strong accomplished objective discuss financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include company file raymond v gilmartin judy c lewent chairman president executive vice president chief executive officer chief financial officer president human health asia audit committee report board director audit committee dismiss arthur andersen llp company independent public accountant february engage pricewaterhousecooper llp serve company independent public accountant fiscal year audit committee comprise independent director meet independent public accountant management internal auditor assure carry respective responsibility audit committee discuss receive letter independent public accountant confirm independence independent public accountant internal auditor access committee include regular meeting management present audit committee meet independent public accountant discuss fee scope result audit work include adequacy internal control quality financial reporting committee discuss independent public accountant judgment quality acceptability company accounting principle clarity disclosure degree aggressiveness conservatism accounting principle underlie estimate audit committee review discuss audit financial statement management recommend board director financial statement include company file security exchange commission heidi g miller lawrence bossidy chairperson thomas e shenk samuel thi merck co inc annual report table content compensation benefit committee report compensation benefit committee comprise independent director approve compensation objective policy employee set compensation company executive officer committee seeks ensure reward closely link company division team individual performance committee seek ensure compensation benefit set level enable merck attract retain highquality employee committee view stock ownership vehicle align interest employee company stockholder consistent longterm focus inherent company rdbase pharmaceutical business policy committee high proportion executive officer compensation dependent longterm performance enhance stockholder value lawrence bossidy william g bowen chairperson johnnetta b cole william n kelley report independent public accountant stockholder board directors merck co inc opinion accompany consolidated balance sheet december relate consolidated statement income retain earning comprehensive income cash flow present fairly material respect financial position merck co inc subsidiary december result operation cash flow year end conformity accounting principle generally accept united states america financial statement responsibility company management responsibility express opinion financial statement base audit conduct audit statement accordance auditing standard generally accept united states america require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audit provide reasonable basis opinion financial statement merck co inc december year period end december prior additional disclosure note audit independent accountant cease operation independent accountant express unqualified opinion financial statement report date january discuss note financial statement company adopt statement financial accounting standard sfas goodwill intangible asset effective january discuss financial statement merck co inc december year period end december audit independent accountant cease operation describe note financial statement revise include transitional disclosure require sfas goodwill intangible asset adopt company january audit transitional disclosure contain note opinion transitional disclosure note appropriate engage audit review apply procedure financial statement company respect disclosure accordingly express opinion form assurance financial statement take florham park pricewaterhousecooper llp new jersey january follow copy audit report previously issue arthur andersen llp connection merck co incs file annual report year end december audit report reissued arthur andersen llp connection filing company annual report exhibit discussion consolidate balance sheet december consolidate statement income retain earning comprehensive income cash flow year end december include accompany financial statement stockholder board directors merck co incwe audit accompany consolidated balance sheet merck co inc new jersey corporation subsidiary december relate consolidated statement income retain earning comprehensive income cash flow year period end december financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance auditing standard generally accept united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect financial position merck co inc subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states new york new york arthur andersen llp january merck co inc annual report table content select financial datum merck co inc subsidiarie million share amount result year sale material production cost market administrative expense research development expense acquire research equity income loss affiliate gain sale business restructure charge income expense net income taxis tax income net income basic earning common share earning common share assume dilution dividend declare dividend pay common share capital expenditure depreciation yearend position work capital property plant equipment net total asset longterm debt stockholder equity financial ratio net income sale average total asset yearend statistic average common share outstanding million average common share outstanding assumingdilution million number stockholder record number employee amount include impact medco health acquisition november result operation exclude cumulative effect accounting change increase inclusion medco health employee merck co inc annual report exhibit merck co inc subsidiary subsidiary set forth business state subsidiary subsidiary indicate indentation immediate parent voting security subsidiary name own directly indirectly company indicate country state incorporation chibret denmark cm delaware llc delaware hangzhou msd pharmaceutical company limited china hawk falcon llc delaware international indemnity ltd bermuda johnson johnsonmerck consumer pharmaceutical company new jersey mcm vaccine co pennsylvania merck company incorporate delaware merck sh inc delaware merial limitedllc great britain delaware british united turkeys limited great britain turkey research development limit great britain merck capital resources inc delaware msd technology lp delaware merck finance co inc delaware merck hamilton inc california merck capital ventures llc delaware merck cardiovascular health company nevada msp distribution service c llc nevada msp marketing service c llc nevada merck enterprises canada ltd canada merck foreign sales corporation ltd bermudamerck holdings inc delaware chippewa holdings llc delaware algonquin sarl luxembourg frosst laboratories inc delaware frosst portuguesaprodutos farmaceutico lda portugal istituto gentili spainc italydelaware kbi inc delaware kbi sub inc delaware kbie inc delaware kbip inc delaware merck borinquen holdings inc delaware merck sharp dohme quimica de puerto rico inc delaware merckmedco holdings ii corp delaware cloverleaf international holdings sa luxembourg brc ltd bermuda coordinate patient care scandinavia norway infodoc norway infodoc international norway medco holdings de rl de cv mexico medco de mexico managed care de rl de cv mexico medco servicios de mexico de rl de cv mexico farmacoxcompanhia farmaceutica lda portugal farmasixprodutos farmaceuticos lda portugal fontelaborproduto farmaceutico lda portugal gestion integrada de salud analisis de resultados evidencia medichip sl spain merck sharp dohme asia pacific services pte ltd singapore merck sharp dohme australia pty limited australia amrad pharmaceuticals pty ltd australia merck sharp dohme finance europe limit great britain merck sharp dohme bv netherlands abello farmacia sl spain financiere msd sas france aventis pasteur msd gestion sa france aventis pasteur msd snc france aventis pasteur msd denmark aventis pasteur msd gmbh austria aventis pasteur msd gmbh germany aventis pasteur msd ltd great britain aventis pasteur msd ltd ireland aventis pasteur msd nvsa belgium aventis pasteur msd sa spain aventis pasteur msd spa italy pasteur vaccin sa france laboratoire martinjohnson johnsonmsd sas france laboratoire merck sharp dohmechibret snc france msd nippon holdings bv netherlands banyu pharmaceutical company ltd japan banyuasc co ltd japan nippon merckbanyu co ltd japan laboratorios biopat sa spain laboratorios chibret sa spain laboratorios frosst sa spain laboratorios neurogard sa spain merck sharp dohme gmbh austria merck sharp dohme holdings de mexico sa de cv mexico merck sharp dohme de mexico sa de cv mexico merck sharp dohme israel company ltd israel merck sharp dohme italia spa italy centra medicamenta otc spa italy istituto di richerche di biologia molecolare spa italy msd proprietary limited south africa msd sharp dohme gmbh germany chibret pharmazeutische gmbh germany dieckmann arzneimittel gmbh germany woelm pharma gmbh co germany msd chibropharm gmbh germany msd unterstutzungskasse gmbh germany varipharm arzneimittel gmbh germany sharp dohme sa spain merck sharp dohme chibret ag switzerland merck sharp dohme de venezuela srl venezuela merck sharp dohme holding limit great britain charles e frosst uk limit great britain merck sharp dohme limit great britain johnson johnsonmsd consumer pharmaceutical limit great britain msd foundation limit great britain thomas morson son limited great britain merck sharp dohme idea inc switzerland merck sharp dohme doo croatia merck sharp dohme tunisie sar l tunisia merck sharp dohme sweden ab sweden merck sharp dohme trading service limit liability company hungary msd ireland holdings sa luxembourg european insurance risk excess limited ireland fregenal holdings sa panama frosst iberica sa spain laboratorios abello sa spain laboratorios quimicofarmaceutico chibret lda portugal merck sharp dohme de espana sa spain merck sharp dohme limitada portugal msd finance bv netherland msd overseas manufacturing co bermuda blue jay investments cv netherlands msd ireland investment ltd bermuda msd latin america services ltd bermuda msd overseas manufacturing co ireland ireland tradewinds manufacture srl barbado msd technology singapore pte ltd singapore msp singapore company llc delaware msdsp ltd great britain msdessex gmbh switzerland msp singaporesub llc delaware msd warwick manufacturing ltd bermuda msd somerset ltd bermuda crosswind bv netherlands merck sharp dohme ireland ltd bermuda msd pembroke ltd bermuda merck sharp dohme puerto rico ltd bermuda merck sharp dohme singapore ltd bermuda transrow manufacturing ltd bermuda neopharme spa italy msd norge norway msd ventures singapore pte ltd singapore ruskin limited bermuda suoman msd oy finland kiinteisto oy viistotie finland merck frosst canada co canada maple leaf holding srl barbados merck frosst canada ltd canada msd japan co ltd japan merck sharp dohme ia corp delaware merck sharp dohme argentina inc delaware msd korea ltd koreadelaware merck sharp dohme ilaclari limited sirketi turkey merck sharp dohme farmaceutica ltda brazil prodome quimica e farmaceutica ltda brazil merck sharp dohme international limited bermuda merck sharp dohme asia limited hong kong merck sharp dohme china limited hong kong merck sharp dohme sas france merck sharp dohme international service bv netherlands merck sharp dohmelebanon sal lebanon merck sharp dohme llc russian federation merck sharp dohme middle east limited cyprus merck sharp dohme pakistan limited pakistan merck sharp dohme sarl morocco merck technology company inc nevada msp technology company llc delaware merck ventures inc delaware msd lakemedel scandinavia aktiebolog sweden readington holdings inc new jersey stellarx inc nevada telerx marketing inc pennsylvania merck institute vaccinology delaware merck investment co inc delaware merck liability management company delaware merck lmc cash management bermuda ltd bermuda merck lmc cash management inc delaware medco health solutions inc delaware dmmg llc delaware medcocal inc california medcohealthcom llc new jersey medco containment insurance company new jersey new jersey medco containment insurance company new york new york medco containment life insurance company pennsylvania medco health llc delaware medco health solution columbus north ltd ohio medco health solution columbus west ltd ohio medco health solutions henderson nevada llc delaware medco health solution hide river lc florida medco health solution las vegas inc nevada medco health solution mechanicsburg llc pennsylvania medco health solution netpark llc delaware medco health solution north versailles llc pennsylvania medco health solution parsippany llc new jersey medco health solution richmond llc virginia medco health solution sabal park lc florida medco health solutions spokane inc washington medco health solution texas llc texas medco health solution willingboro llc new jersey merckmedco willingboro urban renewal llc new jersey merckmedco rx services florida lc florida merckmedco rx services massachusetts llc massachusetts merckmedco rx services new york llc new york merckmedco rx services oklahoma llc oklahoma mw holdings llc delaware njre llc new jersey national rx services inc missouri missouri national rx services inc ohio ohio new york pay independent practice association llc new york nrx federal corp delaware pay direct inc delaware provantage health services inc delaware bravell inc wisconsin pharmark corporation delaware provantage mail services inc minnesota provmed llc wisconsin pvhs inc delaware replacement distribution center inc ohio rxhub llc delaware institute effectiveness research llc delaware systeme llc delaware xceleron health llc delaware merck resource management inc delaware merck respiratory health company nevada msp distribution service r llc nevada msp marketing service r llc nevada merck sharp dohme europe inc delaware merck sharp dohme industria quimica e veterinaria limitada brazil merck sharp dohme new zealand limited new zealand merck sharp dohme overseas finance nv neth antille merck sharp dohme panama sa panama merck sharp dohme peru srl peru merck sharp dohme philippines inc philippine msd international holdings inc delaware rosetta inpharmatics llc delaware exhibit notice consent arthur andersen llp section securities act amend securities act provide case registration statement effective contain untrue statement material fact omit state material fact require state necessary statement mislead person acquire security prove time acquisition person know untruth omission sue accountant consent name prepare certify registration statement prepare certify report valuation connection registration statement respect statement registration statement report valuation purport prepare certify accountant company consolidate financial statement year end include audited arthur andersen llp arthur andersen issue audit report date january consolidated financial statement audit report copy include incorporate reference company previously file registration statement form nos form nos collectively registration statement february company dismiss arthur andersen independent public accountant engage pricewaterhousecooper llp serve company independent public accountant fiscal year company understand staff securities exchange commission take position accept consents arthur andersen engagement partner manager company audit long arthur andersen engagement partner manager company audit long arthur andersen arthur andersen cease practice security exchange commission result company unable obtain arthur andersens write consent incorporation reference registration statement audit report respect company financial statement circumstance rule security act permit company file incorporate reference registration statement write consent arthur andersen arthur andersen consented inclusion audit report registration statement arthur andersen liability section security act untrue statement material fact contain financial statement audit arthur andersen incorporate reference registration statement omission material fact require state accordingly investor able assert claim arthur andersen section securities act purchase security registration statement date exhibit power attorney undersign appoint celia colbert kenneth c frazier severally hisher true lawful attorney attorney execute behalf undersign behalf company officer director thereof attesting seal company annual report merck co inc fiscal year end december securities exchange act include amendment thereto